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 ABSTRACT 
Cytomegalovirus (CMV) infection is a common opportunistic infection after heart 
and lung transplantation. The aims of this thesis were to relate the incidence and 
severity of CMV infection and disease to different forms of antiviral prevention and 
to evaluate whether CMV is a risk factor for bronchiolitis obliterans syndrome (BOS) 
after lung transplantation and coronary artery vasculopathy (CAV) after heart 
transplantation. 
CMV disease had a significant negative impact on 10-year survival as compared with 
no CMV infection in a study of 187 lung transplant patients. CMV prevention with 
14 weeks of oral ganciclovir reduced the incidence and severity and prolonged the 
time to onset of CMV disease, as compared with four weeks of intravenous 
ganciclovir in CMV seropositive patients. Our finding supports the hypothesis that a 
longer duration of CMV prophylaxis is beneficial to lung transplant patients (Paper 
I).  
BOS-free 4-year survival was significantly reduced with CMV disease as compared 
with no CMV infection. A lower incidence of CMV infection/disease and acute 
cellular rejection was observed with valganciclovir (3 months) when compared with 
oral ganciclovir (3 months), in CMV seropositive lung transplant patients. We 
concluded that CMV disease reduces BOS-free survival and that CMV prevention 
with valganciclovir is superior compared with oral ganciclovir in lung transplant 
patients (Paper II). 
Survival and CAV-free survival were significantly reduced in heart transplant 
patients with CMV disease and asymptomatic CMV infection compared with no 
CMV infection after a 10-year follow-up in a study of 226 patients. Our study 
supports the use of an aggressive strategy for reducing not only CMV disease but 
also asymptomatic infection after heart transplantation (Paper III). 
Low-dose valganciclovir prophylaxis (450 mg daily) for 3 months to CMV 
seropositive heart transplant recipients prevented CMV disease and significantly 
reduced the number of patients with reactivated asymptomatic CMV infection when 
compared with a pre-emptive approach. We found that low-dose valganciclovir is 
safe and effective, but this has to be confirmed in prospective studies (Paper IV). 
Keywords: heart transplantation, lung transplantation, cytomegalovirus, ganciclovir, 
valganciclovir, bronchiolitis obliterans syndrome, cardiac allograft vasculopathy 
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SAMMANFATTNING PÅ SVENSKA 
Cytomegalovirus (CMV) är ett herpesvirus. CMV infekterar oss vanligtvis 
under uppväxttiden och ger vid normalt immunförsvar inga symptom eller 
feber under några veckor. Viruset finns därefter kvar latent i de stamceller i 
benmärgen som utvecklas till monocyter i blodet och därefter till 
vävnadsmakrofager. Mer än 70 procent av Sveriges befolkning har 
antikroppar mot CMV, som tecken på en genomgången infektion.  
CMV kan reaktiveras hos personer med nedsatt immunförvar och orsaka 
livshotande infektioner. CMV kan även överföras från donatorn vid 
transplantation. Läkemedel som ges för att förhindra avstötning av organ 
leder till ett nedsatt immunförsvar. Utan profylax debuterar CMV vanligtvis 
tre till sex månader postoperativt. Lungtransplanterade patienter har hög risk 
för att insjukna i CMV-sjukdom, medan hjärttransplanterade har en 
intermediär risk. 
Den främsta faktorn som begränsar långtidsöverlevnaden hos hjärt- och 
lungtransplanterade patienter är kronisk rejektion, definierat som 
bronchiolitis obliterans syndrome (BOS) efter lungtransplantation och 
coronary artery vasculopathy (CAV) efter hjärttransplantation. BOS är en 
progressiv lungfunktionsnedsättning och CAV är en progressiv form av 
arterioskleros som drabbar hjärtats kranskärl. 
Målet med avhandlingen var att utvärdera förekomst och svårighetsgrad av 
CMV sjukdom efter transplantation med olika profylaxregimer samt att 
utvärdera om CMV har betydelse för insjuknande i BOS och CAV.  
Lungtransplanterade patienter som insjuknade i CMV-sjukdom, oftast 
lunginflammation, under det första året efter transplantation jämfördes med 
patienter som inte insjuknade i CMV-sjukdom. Tio års uppföljning av 187 
patienter visade att de patienter som insjuknade i CMV-sjukdom drabbades 
av ökad förekomst av BOS. Olika profylaxregimer jämfördes. Med längre 
duration av CMV profylax, insjuknade färre patienter i CMV-sjukdom och 
själva sjukdomen blev lindrigare. Trots tre månaders valganciklovir profylax 
insjuknade 20 procent av de CMV-seropositiva patienterna i CMV-sjukdom.  
Tio års uppföljning av 226 hjärttransplanterade patienter visade att de som 
insjuknade i CMV-sjukdom oftare drabbades av CAV. Även patienter utan 
symptom, men med påvisat CMV virus i blodet insjuknade i CAV. En ny 
profylaxregim med en låg dos av valganciklovir, 450 mg dagligen under tre 
månader till CMV-seropositiva patienter studerades. Inga patienter 
 insjuknade i CMV-sjukdom och enbart en låg nivå av CMV virus fanns i 
blodet under det första året efter transplantation. 
Det är av stor betydelse att CMV profylax optimeras efter transplantation för 
att undvika CMV-sjukdom. Resultatet från dessa studier visar att CMV-
sjukdom under det första postoperativa året har betydelse även på lång sikt 
när det gäller utvecklingen av BOS och CAV.  
 
i 
LIST OF PAPERS  
This thesis is based on the following studies, referred to in the text by their 
Roman numerals. 
I. Johansson I, Mårtensson G, Andersson R. Cytomegalovirus 
and long-term outcome after lung transplantation in 
Gothenburg, Sweden. Scand J Infect Dis. 2010;42(2):129-36. 
 
II. Johansson I. Mårtensson G, Nyström U, Nasic S, Andersson 
R. Lower incidence of CMV infection and acute rejections 
with valganciclovir prophylaxis in lung transplant recipients. 
BMC Infect Dis. 2013; 13:582. 
III. Johansson I, Sigurdardottir V, Friman V, Selimovic N, 
Hanzen L, Nasic S,
 
Nyström U,
 
Andersson R. 
Cytomegalovirus infection and disease reduce 10-year 
cardiac allograft vasculopathy-free survival in heart 
transplant recipients. Submitted 
IV. Johansson I. Andersson R, Sigurdardottir V, Dellgren G, 
Nyström U, Friman V. Low-dose valganciclovir as 
cytomegalovirus reactivation prophylaxis in heart transplant 
patients. Submitted 
 
 
 
 
ii 
CONTENTS 
ABBREVIATIONS ............................................................................................. IV 
1 INTRODUCTION ........................................................................................... 1 
1.1 Lung transplantation ............................................................................. 2 
1.2 Heart transplantation ............................................................................. 3 
1.3 Cytomegalovirus ................................................................................... 5 
1.3.1 Epidemiology ................................................................................ 6 
1.3.2 CMV infection............................................................................... 7 
1.3.3 CMV infection in solid organ transplant patients, direct effects ... 7 
1.3.4 CMV infection in solid organ transplant patients, indirect effects 9 
1.3.5 Risk factors for CMV infection in solid organ transplantations .. 11 
1.3.6 Laboratory diagnosis ................................................................... 12 
1.3.7 Definition of CMV infection ....................................................... 16 
1.3.8 Antiviral drugs for CMV prevention and treatment .................... 17 
1.3.9 Strategies for CMV prevention and treatment............................. 19 
1.4 Acute rejection .................................................................................... 21 
1.4.1 Acute cellular rejection in lung transplant recipients .................. 21 
1.4.2 Acute cellular rejection in heart transplant recipients ................. 22 
1.5 Chronic rejection ................................................................................. 23 
1.5.1 Bronchiolitis obliterans syndrome ............................................... 23 
1.5.2 Cardiac allograft vasculopathy .................................................... 25 
1.6 Immunosuppression ............................................................................ 27 
2 AIMS ......................................................................................................... 30 
3 PATIENTS AND METHODS ......................................................................... 31 
3.1 Lung transplant patients and study design .......................................... 31 
3.2 Heart transplant patients and study design .......................................... 33 
3.3 Definitions in lung transplant patients ................................................ 34 
3.4 CMV prevention and treatment in lung transplant patients ................ 35 
3.5 Immunosuppression in lung transplant patients .................................. 35 
iii 
3.6 Definitions in heart transplant patients ................................................ 36 
3.7 CMV prevention and treatment in heart transplant patients ................ 37 
3.8 Immunosuppression in heart transplant patients ................................. 38 
4 RESULTS ................................................................................................... 39 
4.1 Lung transplant patients ...................................................................... 39 
4.2 Heart transplant patients ...................................................................... 44 
5 DISCUSSION .............................................................................................. 50 
6 CONCLUSIONS .......................................................................................... 56 
7 FUTURE PERSPECTIVES ............................................................................. 58 
8 ACKNOWLEDGEMENTS ............................................................................. 59 
9 REFERENCES ............................................................................................. 61 
 
  
iv 
ABBREVIATIONS 
ACR Acute cellular rejection 
ACV Aciclovir 
AR Acute rejection 
ATG Antithymocyte globulin 
AZA Azathioprine 
BAL Bronchoalveolar lavage 
BO Bronchiolitis obliterans  
BOS Bronchiolitis obliterans syndrome  
CAV Cardiac allograft vasculopathy  
CMV Cytomegalovirus 
CMVIG CMV immunoglobulin 
CNI Calcineurin inhibitor 
CsA Cyclosporine A 
D+/- Donor CMV serostatus 
eGRF Estimated glomerular filtration rate 
EMB Endomyocardial biopsy  
ERL Everolimus 
FEV1 Forced expiratory volume in one second  
GFR Glomerular filtration rate 
HTx Heart transplantation 
v 
IHC Immunohistochemistry 
IL-2 Interleukin-2 
ISHLT The International Society for Heart and Lung Transplantation 
IVIG Intravenous immunoglobulin 
LTx Lung transplantation 
MDRD Modification of diet in renal disease 
mTOR Mammalian target of rapamycin 
MMF Mycophenolate mofetil 
NAT Nucleic acid amplification testing 
PCR Polymerase chain reaction 
QNAT Quantitative nucleic acid amplification testing 
R+/- Recipient CMV serostatus 
SOT Solid organ transplantation 
TAC Tacrolimus 
TBB Transbronchial biopsy 
  
  
  
Inger Johansson 
1 
1 INTRODUCTION 
Heart and lung transplantation can be life-saving therapy for patients with 
severe organ dysfunction with a limited expected survival of about two years 
or less. The first year after transplantation, acute rejections and infections are 
common complications. However, the most important factors for long-term 
survival are the development of cardiac allograft vasculopathy (CAV) in 
heart transplant recipients and bronchiolitis obliterans syndrome (BOS) in 
lung transplant recipients. Both CAV and BOS represent manifestations of 
chronic rejection and are the results of an immunological response to 
prolonged inflammatory reactions of various kinds, including differences in 
HLA antigens between donor and recipient, acute rejections and viral and 
bacterial infections. 
Cytomegalovirus (CMV) is the most common severe viral infection 
following the transplantation of solid organs. In the early transplantation era, 
CMV disease was associated with high morbidity and mortality [1, 2]. 
Among organ transplant recipients, especially in lung transplant, CMV 
pneumonitis has been the most feared infection [2, 3]. Despite CMV 
prophylaxis and treatment, substantial morbidity is still associated with the 
virus. The prevention of CMV may help to reduce the development of 
chronic rejection (i.e. CAV and BOS) and thus help to preserve allograft 
function for the long term; this is the subject of debate.  
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1.1 Lung transplantation 
The first human lung transplantation was performed in 1963 with only 18 
days’ survival [4]. During the following years, only a few patients underwent 
lung transplants. There were some important technical advances prior to 
1980, such as improved extra-corporeal circulation with improved pumps 
and oxygenators, together with respirators. New immonosuppression such as 
ATG was introduced in the 1970s and, at the beginning of the 1980s, a new 
era began, when cyclosporine immunosuppression was introduced. The first 
successful human lung transplantation was performed at Stanford University 
in 1981 [5]. Lung transplant and intestinal transplant recipients have a higher 
incidence of acute and chronic rejection compared with other solid organs, 
which explains why the introduction of more effective immunosuppressive 
treatment was vital for improved results. Monitoring lung pathology, 
including acute rejections using spirometry and transbronchial biopsies, was 
introduced during the latter part of the 1980s, resulting in additional survival 
benefits. As a result, survival began to improve and, in 1986, one patient 
survived for more than two years [6]. In Sweden, the first lung 
transplantations were performed in 1990 in Lund and Gothenburg. These two 
centres are still performing all the lung transplantations in Sweden. 
There are three different types of lung transplantation; single lung, bilateral 
sequential lung and combined heart-lung transplantation. In the 1990s, single 
lung was the most frequent type of transplantation, usually performed on 
recipients with chronic obstructive pulmonary disease (COPD), due to alfa1 
antitrypsin deficiency (A1AT) or idiopathic pulmonary fibrosis (IPF). 
Bilateral sequential lung transplantation was preferred for recipients with 
cystic fibrosis (CF) and pulmonary arterial hypertension (PAH). Combined 
heart-lung transplantation was reserved for patients with Eisenmenger’s 
syndrome (e.g. congenital heart disorders combined with pulmonary 
hypertension) and for some patients with PAH. Today, bilateral sequential 
lung transplantation has become the most common surgical procedure, as this 
type of transplantation has been shown to be associated with better long-term 
survival also for patients previously selected for single lung transplantation 
Patients with end-stage lung disease, where all conventional treatment has 
been tried and with a life expectancy of less than two years are accepted for 
transplantation [7]. The most common pre-transplant diagnoses are COPD, 
IPF, A1AT, CF, PAH [8]. Other end-stage lung diseases are fibrosis due to 
scleroderma, bronchiolitis obliterans due to graft-versus-host disease 
(GVHD) secondary to bone marrow transplantation, sarcoidosis and 
combined heart-lung Eisenmenger syndrome. Re-transplantation due to 
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severe BOS in previously lung-transplanted recipients is performed in 
selected patients. 
The International Society for Heart and Lung Transplantation (ISHLT) has 
created a registry including reports from most heart and lung transplant 
centres worldwide. These data are analysed in annual reports that have 
resulted in the improved selection of suitable donors and recipients and have 
also improved post-transplant management. An example of these results is 
that bilateral sequential lung recipients appear to have a better median 
survival than single lung recipients (6.9 versus 4.6 years respectively) in 
patients where both procedures would have been possible [8]. For adult lung 
transplantations reported to the ISHLT between January 1994 and June 2011, 
the survival rate was 79% at one year, 53% at five years and 31% at 10 years. 
The median survival was 5.6 years. Patients who survived to one year after 
transplant had a median survival of 7.9 years [8]. 
Up to January 2014, a total of 561 lung transplantations had been performed 
at Sahlgrenska University Hospital in Gothenburg. Of them, 39 were re-
transplantations (Figure 1). 
1.2 Heart transplantation 
The first heart transplantation was performed by Christian Barnard in South 
Africa in 1967. The patient survived for three months [9]. In 1968, Stanford 
University performed its first heart transplantation and the patient survived 
for 15 days [10]. New immunosuppression and endomyocardial biopsy 
(EMB) were introduced in the 1970s and made it possible to prevent, treat 
and verify an acute rejection. In the early 1970s, antithymocyte globulin 
(ATG) was introduced as immunosuppressive induction therapy and 
maintenance immunosuppression therapy was similarly improved by the 
introduction of cyclosporine A in 1981. The Stanford group recently reported 
that, between 1968 and 2007 (n=1,446), the one-year survival for heart 
transplant recipients at their centre increased from 43% to 90% [10]. In 
Gothenburg, the first patient was transplanted in 1984 with a donor organ 
from abroad, as the criteria for brain death had not been legislated on. The 
legislation was changed and, since 1988, Swedish heart donors have been 
available, resulting in an increased heart transplant programme. 
The indication for transplantation is heart failure with a poor short-term 
prognosis. The most common pretransplant diagnoses are dilated 
cardiomyopathy, ischemic cardiomyopathy, restrictive cardiomyopathy, 
Cytomegalovirus Infection in Heart and Lung Transplant Patients with focus on long-term-
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hypertrophic cardiomyopathy, valvular heart disease and congenital heart 
diseases.  
For all heart transplantations (both paediatric and adult) reported to the 
ISHLT between 1982 and June 2011, the one-year survival was 85% and the 
five-year survival was 69%. The median survival was 11 years; patients who 
survived the first year had a median survival of 13 years [11].  
In January 2014, a total of 564 heart transplants had been performed at 
Sahlgrenska University Hospital in Gothenburg and of them 15 were re-
transplantions (Figure 1). 
 
 
Figure 1. Heart and lung transplant patients at Sahlgrenska University Hospital 
from January 1988 to December 2014; a total of 1,125 transplantations were 
performed. 
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1.3 Cytomegalovirus 
Cytomegalovirus (CMV) belongs to the family of human herpes viruses. 
CMV was identified in 1956. Viral culture was restricted to human 
fibroblasts, the virus slowly replicated and it was characterised by 
intranuclear inclusion bodies. CMV is named after the appearance of its 
cytopathic effect in cell culture, cytomegalia, which means a large cell. The 
first description of CMV disease in an adult was documented in 1965.  
CMV is the largest virus that infects humans, 150-200 nm in diameter. The 
genome consists of 230 kilo base pair (kbp) double-stranded DNA. The 
genome encodes for a two to three times larger number of gene products than 
any other herpes virus [12]. CMV has four structural elements; core, capsid, 
tegument and envelope. The core contains the linear double-stranded DNA, 
is surrounded by a proteinaceous layer, defined as the tegument or matrix, 
which, in turn, is enclosed by a lipid layer containing a large number of viral 
glycoproteins [13] (Figure 2). 
 
 
 
 
 
 
 
 
 
Figure 2. A schematic image of the cytomegalovirus structure. Reproduced with 
permission from Dr. Marko Reschke. 
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CMV is able to infect a large number of human cell types; fibroblasts, 
granulocytes, monocytes, macrophages, dendritic cells and epithelial and 
endothelial cells [14, 15], and causes disease in most organs, such as 
pneumonitis, myocarditis, gastrointestinal disease, retinitis, hepatitis, 
nephritis and pancreatitis. Like the other herpes viruses, CMV establishes 
latent infection in the host after primary infection and remains mainly in CD 
34+ bone marrow progenitor cells and monocytes [16, 17]. Latent CMV is 
defined by the carriage of the CMV genome without active replication but 
with the ability of the CMV genome to reactivate under specific stimuli [18]. 
In the latent phase, only a few viral genes are expressed and few viral 
proteins are produced and the infected cell is therefore not detected by the 
host immune system. The exact mechanisms that control latency are unclear. 
CMV pathogenesis depends on a balance of viral and host factors. Viral 
factors contributing to the development of CMV infection include the 
amount of virus to which the individual is exposed, as well as the replication 
dynamics of that virus. The growth rate of CMV in immune native patients is 
faster than the growth rate in CMV-experienced transplant patients [19]. The 
presence of other viral and bacterial infections also increases susceptibility to 
infection by CMV. Host factors are donor/recipient serostatus and the 
intensity of immunosuppression. CMV-specific CD4+ and CD8+ lymphocytes 
play an important role in immune protection after primary infection or the 
reactivation of latent disease. 
 
1.3.1 Epidemiology 
The seroprevalence of CMV in the global human population is 
approximately 70% [16] and the rates vary from 45-100%, depending on age, 
country and socio-economic conditions [20]. CMV infection is mostly 
acquired during early childhood and there is a peak in adolescence. 
Following infection, the virus is excreted in body fluid (urine, saliva, tears, 
semen and breast milk and cervical secretion) for a long period 
[13].Transmission of the virus occurs with close contact like that among 
family members and children in day care centres (via urine or saliva). Sexual 
transmission is seen between partners via semen and cervical secretion. CMV 
may be spread vertically; via the placenta during maternal viremia, through 
secretion in the birth canal or from breast milk. Transmission by blood 
transfusion or blood products may occur, but it is uncommon after the use of 
filtered blood was introduced. CMV is transferred with solid organ and bone 
marrow transplantation when the donor is CMV seropositive. 
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1.3.2 CMV infection 
In an immunocompetent host, the primary CMV infection is generally 
asymptomatic or presents as a flu-like syndrome. Acute CMV disease, 
mononucleosis syndrome, only occurs in a small proportion of infected 
individuals. It presents with fever, pharyngitis, sometimes cervical 
lymphadenitis and hepatitis. The spleen may be enlarged. Atypical 
lymphocytes are seen in the blood. Laboratory findings usually disappear 
after six weeks. Fatigue usually persists for several weeks to months. Severe 
disease with organ-specific complications exists, but it is rare [21, 22]. 
 
1.3.3 CMV infection in solid organ transplant 
patients, direct effects 
In organ transplant patients, CMV is the most clinically significant 
opportunistic infection. The virus can cause severe CMV disease, ranging 
from CMV syndrome to tissue invasive disease. CMV syndrome is a flu-like 
illness which may be characterised by fever, malaise, leucopenia, 
thrombocytopenia and the mild elevation of liver enzymes. The occurrence 
of tissue-invasive disease is different in each type of organ transplantation. 
The reported incidence of CMV infection/disease ranges from 38% to 75% in 
lung transplant patients and 9% to 35% in heart transplant patients in the 
absence of prophylaxis [23-25]. Despite an antiviral strategy, CMV has 
remained the most frequent opportunistic infection after organ 
transplantation [26], causing pneumonitis, gastrointestinal disease, 
myocarditis, nephritis, hepatitis, pancreatitis and retinitis. CMV has a 
predilection for invading the transplanted organ.  
In lung transplant patients, the most common CMV disease is pneumonitis. 
CMV pneumonitis can be life threatening if not treated. In single lung 
transplant recipients, the disease affects the transplanted lung almost 
exclusively. The symptoms are fever, cough, tiredness, dyspnoea and 
hypoxia. The clinical symptoms of CMV pneumonitis and acute rejection are 
the same. A transbronchial lung biopsy (TBB) may therefore be needed to 
differentiate between infection and acute rejection. The treatments are 
opposite; acute rejection is treated with increased immunosuppressive 
therapy, while CMV disease is treated with antiviral drugs and reduced 
immunosuppressive therapy. CMV pneumonitis has been shown to be a risk 
factor for invasive aspergillosis following lung transplantation [27]. 
Gastrointestinal CMV disease is the second most common tissue-invasive 
disease in lung transplant recipients.  
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In the early era of heart transplantation, myocarditis and pneumonitis were 
severe complications of the CMV disease. Myocarditis is almost unique to 
heart transplant recipients. An endomyocardial biopsy is required to confirm 
the diagnosis, with viral inclusion bodies or immunohistochemistry (IHC). 
Myocarditis can cause arrhythmia, cardiac dysfunction and even sudden 
cardiac death [22, 28-30]. In heart transplant recipients CMV syndrome and 
gastrointestinal disease are the most common forms of CMV disease 
nowadays. 
Gastrointestinal CMV disease is seen in all types of solid organ transplants. 
The symptoms related to the disease are nausea, vomiting, dysphagia, 
epigastric pain, diarrhea, abdominal cramps and severe gastrointestinal 
bleeding. CMV disease can lead to ulceration or perforation in any part of the 
gastrointestinal tract. The most common location is the stomach, proximal 
small bowel and caecum. Endoscopy shows variable lesions, from erythema 
to deep ulcers [31]. A biopsy and the detection of the virus with histological 
examination and IHC are required for the diagnosis. 
Retinitis is rare in solid organ transplant patients. It causes blurring or loss of 
central vision, scotomata (“blind spots”), floaters, or photopia (“flashing 
lights”). Ophthalmologists diagnose retinitis on the basis of characteristic 
retinal changes. Retinitis is unusual and central nervous system (CNS) 
disease is extremely rare in organ transplant recipients [32]. 
As the CMV virus has a predilection for invading the transplanted organ, 
hepatitis is most frequent in liver transplant recipients, while nephtritis is 
most common in kidney transplant recipients [33].  
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1.3.4 CMV infection in solid organ transplant 
patients, indirect effects 
In addition to the direct effects of invasive CMV infection, CMV has 
possible indirect effects, both general and transplant specific (Figure 3). 
These conditions are called indirect effects of CMV infection, as they are not 
directly related to viral invasion of the tissue. The possible general indirect 
effects include an elevated risk of bacterial, fungal and viral infection [27, 
34, 35], new-onset diabetes mellitus after transplantation [36] and acute 
rejection [37-39].  
 
Figure 3. Overview of CMV infection; direct and indirect effects. Reproduced with 
permission from N Engl J Med. 1988; 338:1741. Copyright Massachusetts Medical 
Society. 
Possible transplant-specific indirect effects that have been discussed are BOS 
after lung transplantation [37, 40-43] and CAV in heart transplant patients 
[39, 44]. The pathogenesis of BOS is the peribronchiolar infiltration of 
lymphocytes, leading to fibrous scarring in the bronchioles and progressive 
airflow obstruction [45]. The pathogenesis of CAV is an initial endothelial 
injury, followed by intimae hyperplasia and the proliferation of vascular 
smooth cells that lead to the diffuse luminal stenosis of the coronary arteries 
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[46]. Other possible indirect effects are chronic allograft nephropathy after 
renal transplantation [47-49], accelerated hepatitis C virus recurrence and 
vanishing bile duct syndrome after liver transplantation [50-52]. 
A model of CMV pathogenesis after solid organ transplantation is described 
by Emery [16] (Figure 4). Latent infection is transferred with the donor organ 
(red spots). The CMV virus becomes activated and thereafter the local spread 
of the virus occurs in the transplant organ over the next seven days. The virus 
may spread through the blood to infect other target organs. The high levels of 
replication, DNAemia, are associated with CMV disease. In addition, early 
graft infection may contribute to the indirect effects shown in the figure. 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Cytomegalovirus: recent progress in understanding pathogeneis and 
control. Figure adapted with permission from Oxford University Press, OJM 2012 
May: 105 (5):401-405. 
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1.3.5 Risk factors for CMV infection in solid 
organ transplantations 
Serostatus  
The impact of CMV serostatus is essential. Seronegative (R-) recipients who 
receive organs from a CMV-positive donor (D+) run the highest risk of CMV 
disease (as a result of the reactivation of latent virus from the transplanted 
organ). Seropositive (R+) recipients who receive organs from a CMV-
positive donor (D+) or CMV-negative donor (D-) run a medium risk of CMV 
disease. Patients with D-/R- serostatus run the lowest risk of CMV infection, 
but they may acquire infection through natural transmission in the 
community settings, or by blood transfusion, if the blood is not leukocyte 
depleted or CMV negative. 
Type of organ 
The incidence of CMV infection and disease is different, depending on the 
type of organ transplanted. McDevitt reported an incidence of CMV disease 
in kidney transplant recipients of 8%, in liver 20%, in heart 25%, in lung or 
heart-lung 39% and in pancreas 50% [24]. Lung and intestinal transplant 
recipients run the highest risk of developing CMV disease. The reason for 
increased CMV disease may be the larger amount of lymphoid tissue in lung 
and intestinal transplant organs and also the higher immunosuppression [53].  
Immunosuppression  
The impact of immunosuppression in the development of CMV 
infection/disease depends on the type of drug, the dose and duration av the 
treatment. The dose is especially high during the first three to six months 
after transplantation. Antithymocyte globulin (ATG) has been associated 
with an increased risk of CMV disease [54]. New maintenance 
immunosuppression as a mammalian target of rapamycin (mTor) inhibitor is 
reported to produce a lower risk of CMV infection [55-57].  
 
Acute rejection  
There is a bidirectional relationship between CMV and acute rejection (AR), 
as acute rejection creates a proinflammatory environment that can reactivate 
CMV and the treatment for acute rejection is augmented 
immunosuppression. Conversely, CMV upregulates antigens, and this result 
in alloreactivity and increases the risk for AR [26, 58, 59].  
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Blood transfusion 
The transfusion of blood products is a risk factor if the blood contains 
leukocytes. Leuko-depleted blood products have significantly reduced the 
risk of transfusion-transmitted CMV [60, 61]. 
1.3.6 Laboratory diagnosis 
The laboratory tests that are available to diagnose CMV are histopathology, 
serology, viral culture, pp65 antigememia and nucleic acid tests (NAT). In 
the early days, serological testing and viral cultures from multiples sites were 
the cornerstone of diagnosis. Today, viral load (quantitative nucleic acid tests 
(QNAT)) or antigenemia are the standards for the diagnosis and monitoring 
of CMV infection and disease. Depending on the method used, CMV 
infection can be termed CMV viremia (culture), CMV antigenemia (viral 
antigen testing) and CMV DNAemia (NAT). 
Serology 
Serology detects CMV-IgM and IgG antibodies. One of the techniques most 
frequently used to detect CMV-specific antibodies is the enzyme-linked 
immunosorbent assay (ELISA). The CMV IgM antibody response following 
primary infection slightly precedes IgG antibody development. The CMV 
IgM antibody reaches a plateau in the first months after the onset of infection 
and then slowly declines in the following three to six months. CMV IgG 
antibodies persist for life and are the quickest assay to detect immunity. 
CMV IgG should be performed before transplantation on both the organ 
donor and the recipient [32]. After transplantation, CMV-IgM and IgG 
antibodies have a limited value for the diagnosis of CMV disease [62]. The 
high level of immunosuppression after transplantation results in a delayed or 
impaired ability to produce antibodies. The transfusion of blood products 
may produce a false positive test (via the passive transfer of antibodies). In 
the early days, seroconversion (the appearance of IgM and IgG antibodies in 
a previously seronegative individual) was used to diagnose CMV infection. 
Another possibility was to detect a fourfold increase in CMV IgG titres in 
paired specimens obtained at least two or four weeks apart.  
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Histopathology 
Histopathology is the preferred method for confirming tissue-invasive CMV 
disease. Typical morphological changes, large cells (cytomegalia) with viral 
inclusion bodies (“owl’s eye”), are found in a biopsy from an affected organ 
(Figure 5). The method is used together with IHC with monoclonal 
antibodies to detect CMV antigen. The histological detection of owl’s eye 
inclusion bodies is a highly specific method for detecting CMV organ 
involvement, but its sensitivity is low. This method has been used since the 
early era of transplantation and it is still used albeit less frequently [63, 64]. 
Its invasive procedure has limited its use. If the transplanted organ is 
affected, a biopsy could be required to differentiate between acute rejection 
and CMV infection. A biopsy for histopathology is also needed when the 
symptoms persist despite the treatement of CMV disease, but CMV testing in 
the blood is negative, which may occur in some cases of gastrointestinal 
disease [65]. The detection of large cells with viral inclusion bodies and 
CMV antigen detection by IHC can also be used in BAL fluid [66]. In 
particular, alveolar macrophages appear to be the cell containing CMV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Cytomegalovirus infection in the lung. Histopathology shows cytomegalic 
pneumocytes containing characteristic intranuclear inclusions. Downloaded from 
open domain, commons.wikimedia.org 
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Viral culture 
Viral culture is highly specific for the detection of CMV and CMV can be 
isolated from multiple specimen types, such as blood, urine, cerebrospinal 
fluid, BAL fluid and from tissue biopsy. However, the culture of human 
fibroblasts routinely takes two to four weeks and the sensitivity is modest. 
The test therefore has limited use in diagnosing infection or disease in 
transplant recipients. A positive blood culture is specific and predictive of 
CMV disease. The detection of CMV in cultures from other sites does not 
confirm active disease, as seropositive recipients may shed CMV in their 
secretions; a positive viral culture from urine is not specific for active CMV 
disease [67]. Viral culture is the method used when phenotypic antiviral drug 
resistance testing is requested. However, for the clinical diagnosis of drug 
resistance, the phenotypic methods are too time-consuming. 
The antigenemia assay 
The antigenemia assay is a semi-quantitative test that detects pp65 antigen in 
CMV-infected peripheral blood leukocytes [68]. The test has higher 
sensitivity than cultures and has been used at several centres to diagnose 
acute CMV infection and to guide pre-emptive therapy [69]. The main 
disadvantage is the need to process the clinical sample within a few hours (6-
8 hours), as the test relies on leukocytes. Leucopenia is thus a limitation; an 
absolute neutrophil count of less than 1,000/mm
3 
diminishes the performance 
of the assay [70]. 
Quantitative nucleic acid tests (QNAT)/polymerase chain 
reaction (PCR) 
Quantitative nucleic acid tests (QNAT)/polymerase chain reaction (PCR) are 
the most commonly used molecular assay today [71, 72]. The method is used 
for the diagnosis of active disease, monitoring the response to the therapy 
and monitoring when pre-emptive therapy is used as a prophylactic approach. 
Most laboratories use real-time PCR. Compared with the previously used 
conventional PCR method, the advances with real-time PCR are a broader 
linear range, more rapid turnaround time and reduced risk of carryover 
contamination [73]. Both whole-blood and serum specimens are used to 
detect CMV viral load. It is important to use the same specimen when 
monitoring with quantitative real-time PCR over time. Whole blood often 
gives a higher viral load compared with plasma, as blood measures both cell-
free and intracellular viruses [74]. There has been variability in the test 
results (viral load) from laboratories at different centres due to the lack of 
standardisation [75]. Different results could be explained, as there are 
differences in commercial detection reagents, primers and probes targeting 
different genes, methods for extracting nucleic acid and calibration, among 
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others. In 2010, the World Health Organisation (WHO) therefore released an 
international reference for the quantification of CMV nucleic acid, which 
enables assay calibration and standardisation among laboratories. In a recent 
multinational study, five different laboratories showed good reproducibility 
in viral load values when using a commercial test, which was calibrated to 
the WHO standard [76]. In earlier days, only qualitative CMV PCR was 
available. This is also a sensitive test, but it is unable to differentiate low-
level from high-level viral replication and is therefore not a valuable test 
when monitoring the effect of CMV treatment. Genotypic resistance testing 
is now routinely used for the diagnosis of drug resistance.  
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1.3.7 Definition of CMV infection  
The following definitions are adapted from Ljungman et al. [31]. 
 
Primary infection is the detection of CMV infection in an individual 
previously found to be CMV seronegative.  
Reinfection or superinfection is the detection of a CMV strain that is 
distinct from the strain that was the cause of the patient’s original infection. 
Reactivation is assumed if the CMV strain detected in the previous infection 
is found to be indistinguishable from the strain causing the new episode. 
 
 
The following definitions are in accordance with Kotton et al. [32], and 
Razonable et al. [77].  
CMV infection: evidence of CMV replication regardless of symptoms 
(differs from latent CMV)  
 
 Asymptomatic CMV infection: evidence of CMV infection without 
clinical symptoms  
 
CMV disease: evidence of CMV infection with attributable symptoms 
classified as:  
 CMV syndrome: viral syndrome with fever and/or malaise, 
leukopenia and/or thrombocytopenia 
 
 Tissue-invasive CMV disease, proven: symptoms and signs of 
disease and CMV detected by immunohistochemistry (IHC) with 
CMV-specific antibodies in a biopsy from the affected organ. The 
definitive diagnosis relies on the detection of CMV in the tissue 
specimen, with the exception of central nervous system disease and 
retinitis.  
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1.3.8 Antiviral drugs for CMV prevention and 
treatment  
Drugs that have been evaluated for prophylaxis in heart and lung transplant 
recipients are aciclovir, ganciclovir, valganciclovir and immune globulin 
preparations. 
Aciclovir/valaciclovir 
Aciclovir is a nucleoside analogue of guanosine and a homologue of 
ganciclovir. At the beginning of the 1990s, aciclovir was used as CMV 
prophylaxis in lung transplant patients. Valaciclovir is the prodrug of 
aciclovir. Prophylaxis is only recommended in kidney transplant patients. 
The recomended prophylaxis dose of valaciclovir is 2,000 mg p.o. four times 
daily [77], but a lower dose of valaciclovir, 1,000 mg three times daily to 
D+/R-, has also been shown to be effective [78, 79]. Valaciclovir is not 
recomended for the treatment of CMV disease. 
Ganciclovir 
Ganciclovir is a nucleoside analogue of guanosine and a homologue of 
aciclovir. The phosporylation of the drug is required to have an effect. Its 
mechanism of action is through the inhibition of virally encoded DNA 
polymerase [80]. Ganciclovir is excreted in urine and the dose has to be 
adjusted for renal function. Clearance is directly correlated to the glomerular 
filtration rate. The plasma half-life is two to four hours; the intracellular half-
life of ganciclovir triphosphate is about 16.5 hours. The major toxicity is to 
the bone marrow and neutropenia is especially common. Granulocyte colony 
stimulating factor (G-CSF) can be used, together with ganciclovir, if needed, 
to increase the leukocyte count, if severe neutropenia occurs. 
Intravenous ganciclovir has been the drug of choice for prophylaxis and 
treatment since the beginning of the 1990s. Oral ganciclovir has been used as 
prophylaxis at our transplant unit since 2000 and has made it possible to give 
a longer duration of prophylaxis. The bioaviability is only 6-9%. The drug 
has never been used as treatment for CMV disease in solid organ transplants. 
At our transplant unit, oral ganciclovir was replaced by valganciclovir in 
2003/2004. The recommended treatment dose is 5 mg/kg of i.v. ganciclovir 
every 12 hours. The prophylaxis dose is 5 mg/kg i.v. once daily. Oral 
ganciclovir is not recommended for treatment; the prophylaxis dose is 1,000 
mg three times daily.  
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Valganciclovir 
Valganciclovir is a valine ester of ganciclovir, i.e. a prodrug of ganciclovir. 
The mechanism of this drug is activation via a viral protein kinase HCMV 
UL97 and subsequent phosphorylation by cellular kinases. It is well absorbed 
after oral administration and rapidly hydrolysed to ganciclovir in the 
intestinal wall and liver. The bioavailability of ganciclovir from 
valganciclovir tablets is approximately 60%. A dose of 900 mg of 
valganciclovir daily can achieve systemic exposure similar to 5mg/kg of i.v. 
ganciclovir daily [81]. The adverse effects are similar to ganciclovir and 
valganciclovir thus has to be adjusted for renal function and is associated 
with bone marrow suppression, particularly leucopenia. Valganciclovir can 
be used as treatment in mild or moderate CMV disease. The recommended 
treatment dose of valganciclovir is 900 mg twice daily and the prophylaxis 
dose is 900 mg once daily. 
Foscarnet 
Foscarnet is a pyrophosphate analogue that directly inhibits the CMV DNA 
polymerase [82]. In heart and lung transplant patients, the drug is principally 
used for the treatment of ganciclovir-resistant CMV. The most common 
adverse effects are renal impairment, electrolyte imbalance, anaemia and 
granulocytopenia. The recommended treatment dose is 60 mg/kg i.v. every 
eight hours. It is not recomended for prophylaxis. 
Cidofovir 
Cidofovir is a nucleotide analogue of cytosine. Cidofovir is converted by 
cellular enzymes to cidofovir triphosphate, which is an active inhibitor of 
viral DNA polymerase. The adverse event is dose-dependent nephrotoxicity. 
The treatment dose is 5 mg/kg once weekly x 2 and then every two weeks 
thereafter. Cidofovir is used in the event of ganciclovir resistance and is not 
recommended for prophylaxis. The drug is not well studied in solid organ 
transplant. 
The recomended doses of prophylaxis  and treatment is adapted from the 
American Society of Transplantation [77].  
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Intravenous immunoglobulin (IVIG) 
CMV-specific immunoglobulin (CMV-IVIG) has been given as prophylaxis 
to lung transplant recipients, mostly in combination with intravenous 
ganciclovir. CMV-IVIG or IVIG is sometimes used in combination with 
i.v.ganciclovir in severe CMV pneumonitis. The effect is believed to be 
immunomodulatory and limits acute inflammatory events [59]. The efficacy 
of this approach is debatable. 
Ganciclovir resistance 
Ganciclovir resistance is observed especially after prolonged exposure to the 
drug, suboptimal ganciclovir levels and together with intensive 
immunsuppression. Gancilovir resistance is more common after lung 
transplantion, in CMV D+/R- and in patients with a high viral load of CMV 
DNA in blood or serum. Ganciclovir resistance is caused by mutations in the 
viral UL97 (coding for viral proteinkinase, which is responsible for the 
phosphorylation of ganciclovir) or UL54 genes (coding for CMV DNA 
polymerase). In patients treated with ganciclovir, UL97 mutations appear 
first in about 90% of cases, but UL54 mutations may follow later. Mutation 
in UL54 is associated with a higher level of resistance to ganciclovir or 
cross-resistance to foscarnet or cidofovir [83]. Mutations in UL97 do not 
affect foscarnet or cidofovir and the drugs can be used as treatement. 
 
1.3.9 Strategies for CMV prevention and 
treatment  
Universal prophylaxis  
Universal prophylaxis is the administration of an antiviral drug to all patients 
at risk of CMV infection (i.e. all patients except for D-/R-) during a fixed 
period of time. Antiviral medication starts immediately or very early after 
transplantation and most often continues for three to six months [32] and 
even longer for lung transplant recipients [84]. The advantages of universal 
prophylaxis are that it is easy to administer, less monitoring with QNAT is 
needed and the drug also protects from other herpes viruses, such as the 
herpes simplex virus and varicella zoster virus [32]. The disadvantages are 
increased drug toxicity, drug-related cost and the risk of resistance 
emergence. After the cessation of the antiviral drug, there is a risk of 
developing CMV disease (i.e. late-onset disease) [85].  
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Targeted prophylaxis 
Targeted prophylaxis involves the administration of antiviral drugs in clinical 
circumstances when patients are at high risk of CMV disease, such as 
lymphocyte-depleting induction immunosuppression [26]. 
Pre-emptive therapy 
Using the pre-emptive therapy approach, patients are monitored at regular 
intervals to detect early viral replication. Once viral replication reaches a 
certain threshold, antiviral treatement is initiated. These laboratory methods 
include the CMV pp65 antigenemia assay and QNAT for the detection of 
CMV DNA from blood or serum. Treatment is thus given to prevent the 
progression of asymptomatic infection to disease. The pre-emptive approach 
requires frequent monitoring and can be difficult to practise if the patients 
live far away from the hospital or laboratory. Once CMV is reactivated, the 
viral load may increase very rapidly [86]. Emery et al. reported a doubling 
time of approximately 24 hours [87]. Only one assay and one specimen type, 
either whole blood or plasma, should be used to compare the difference in 
viral load. Whole blood often gives a higher viral load compared with 
plasma. The advantages are reduced toxicity, drug cost and a lower rate of 
late-onset disease. 
Treatment 
Antiviral therapy is given to patients with symptomatic CMV disease, most 
often i.v. ganciclovir with two to three weeks’ duration. In mild or moderate 
CMV disease, valaganciclovir is an alternative. The treatment should be 
continued until CMV is undetectable; today, this is often monitored once a 
week with CMV DNA from blood or serum. 
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1.4 Acute rejection 
All solid organ transplant recipients are at risk of acute cellular rejections 
(ACR). The histopathology of an ACR is characterised by the infiltration of 
mononuclear white blood cells, predominantly activated lymphocytes and 
monocytes/macrophages. The lymphocytotoxic activity causes tissue 
damage. The risk factors for ACRs are differences in antigens between donor 
and recipient (HLA, ABO), to low doses of immunosuppressive treatment, 
infections and other specific or unspecific inflammatory reactions. 
1.4.1 Acute cellular rejection in lung transplant 
recipients 
Acute cellular rejection (ACR) in the initial post-operative phase is often 
associated with clinical symptoms such as breathlessness, chest tightness and 
subfebrility. Chest radiographs show parenchymal infiltrates or pleural 
effusion and laboratory analyses show leukocytosis. After the initial post-
operative phase, ACRs may be asymptomatic at the time of pathological 
diagnosis. When patients have symptoms, they vary from subfebrility, 
dyspnea and cough or sputum production to acute respiratory distress. ACRs 
are associated with a reduction in lung function tests, above all FEV1. 
Regular daily measurements of lung function, using various 
microspirometers and performed by the patients at home, have proven to be a 
useful tool in predicting episodes of ACR [88]. These tests do not distinguish 
between ACR, infections or other lung disorders but are indicators of a 
pathological disorder in the lung. When ACR is suspected, it can be verified 
by performing bronchoscopic transbronchial lung biopsies (TBBs). Many 
centres perform scheduled surveillance biopsies at various time points and 
then in addition when ACR or other lung pathology is suspected. 
Microscopic examination shows lymphocytic perivascular or peribronchiolar 
infiltrate in the lung tissue [89]. The majority of these mononuclear cells are 
T-cells and CD8+ T cells are most common [90]. Rejections in the lung are 
graded according to ISHLT guidelines into type A, B, C and D; A represents 
ACR, B represents bronchial inflammation, C represents chronic bronchial 
rejection including bronchiolitis obliterans (BO) and D chronic vascular 
rejection. Type A is in turn divided according to severity into grade 0, 1, 2, 3 
and 4, where 0 represents no signs of ACR, 1 represents minimal signs of 
ACR, 2 mild signs of ACR, 3 moderate signs of ACR and 4 represents severe 
signs of ACR. Normally, only ACRs of category > 2 need to be treated [89]. 
The incidence of ACR is most frequent during the first three to six months. 
ACR decreases with time and is rare after three years post transplantion. 
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Differential diagnoses during this time include CMV infection and 
pneumonia with pneumocystis jirovecci, among others. 
 
1.4.2 Acute cellular rejection in heart transplant 
recipients 
Symptoms of ACR in the heart-transplanted recipient vary from none to 
malaise, low-grade fever, dyspnea, weight gain and palpitations. ACRs are 
more frequent during the first three to six months. There is no reliable non-
invasive method for monitoring the occurrence of an ACR and myocardial 
biopsies are therefore often performed according to a fixed time schedule 
during the initial post-operative months and, in addition, as needed due to 
symptoms and signs. Microscopic examination usually shows lymphocytic 
perivascular, interstitial and muscular tissue infiltration. CD3-reactive T-
lymphocytes and macrophages are involved [91]. Until 2004, ACR was 
graded according to ISHLT into grade 0, 1, 2, 3 and 4, but a new grading 
system was introduced in 2004 and, since 2007, it has been applied at our 
transplant centre. According to the new classification, grade 0 represents no 
signs of ACR, grade 1 mild, grade 2 moderate and grade 3 severe ACR [91].  
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1.5 Chronic rejection 
In lung transplantion chronic rejection is called bronchiolitis obliterans 
syndrome (BOS). In heart transplantation chronic rejection is called cardiac 
allograft vasculopathy (CAV). Other names for CAV are graft coronary 
artery disease, graft coronary vascular disease, transplant coronary artery 
disease and accelerated graft arteriosclerosis. 
1.5.1 Bronchiolitis obliterans syndrome  
Bronchiolitis obliterans (BO), also called obliterative bronchiolitis (OB), is 
the histological diagnosis of chronic allograft rejection; the peribronchiolar 
infiltration of lymphocytes, leading to fibrous scarring in the bronchioles. 
The histological confirmation of BO is difficult because transbronchial 
biopsy specimens are often not sensitive enough and BOS based on 
pulmonary function tests has therefore been introduced and is used as a 
surrogate marker of BO [45, 92]. 
The definition of BOS is chronic allograft dysfunction/chronic rejection 
defined as a progressive airflow obstruction not explained by acute rejection, 
infection or other confounding complication [45]. Spirometry is a standard 
method for monitoring lung transplant recipients. In order to monitor for the 
new onset of impaired allograft function, a baseline value for FEV1 is 
assessed shortly after transplantation. A baseline value is used for 
comparison with FEV1 values measured later and to calculate a patient’s 
BOS grade. BOS grade 1 has an FEV1 of 65-80%, BOS grade 2 has an FEV1 
of 50%-65% and BOS grade 3 an FEV1 of less than 50% of the baseline 
value.  
Clinically, progressive airflow limitation develops with symptoms of 
dyspnea and non-productive cough. The more advanced stages of BOS are 
associated with dyspnea at rest and with a productive cough if bronchiectasis 
has developed. BOS has remained a major source of morbidity and mortality 
in lung transplant recipients. It is present in 49% of recipients five years after 
lung transplantation and, at 10 years, the rate reaches 75% [93]. The disease 
has an unpredictable course; some patients develop rapid loss of pulmonary 
function, whereas other patients have a slow or intermittent loss of function. 
In most patients, BOS is a progressive process for some years.  
 
Many factors have been reported as risk factors for BOS [94, 95]. The role of 
antibody-mediated rejection is a source of ongoing investigation and debate 
[96]. Alloimmunological injury directed against the endothelial and epithelial 
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structures has been thought to mediate BOS. Probable risk factors for BOS 
are acute rejection, lymphocytic bronchitis/bronchiolitisis, CMV pneumonitis  
and medication non-compliance [45]. Acute rejections predispose for BOS, 
especially if they are frequent, long lasting or severe [97, 98]. 
Gastroesophageal reflux is common in and may contribute to BOS via acid 
aspiration [99, 100]. Different definitions of CMV infection and disease, 
CMV pneumonitis and different prophylactic strategies among institutions 
have made it difficult to interpret CMV as a risk factor for BOS. The 
following studies report that CMV infection is a reason for the development 
of BOS [41, 42, 101-104], but other studies have not found any impact of 
CMV infection on the onset of BOS [105, 106]. Community-acquired 
respiratory viruses (CARV) as a risk factor for BOS are discussed. Gottlieb 
et al. report that symptomatic CARV infection increases the risk of the new 
onset of BOS but not the progression of BOS [107]. Kumar et al. found that, 
in some patients, CARV infection is a trigger for AR and BOS [108]. 
Transplant type, single more than bilateral lung transplantation, may be a risk 
factor for BOS [109]. Bronchoscopy with BAL is valuable in excluding other 
reasons for airflow limitaton on spirometry, such as AR, infection, 
malignancy and stenosis at the anastomotic site, before the diagosis of BOS 
is made. The potential prevention for BOS includes aggressive initial 
immunosuppression to eliminate AR during the first year(s), prophylaxis 
against CMV infection, the treatment of gastroesophagal reflux to reduce 
acid aspiration and long-term azitromycin (generally 250 mg orally three 
times weekly) [110, 111]. No effective treatment for BOS exists.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inger Johansson 
25 
1.5.2 Cardiac allograft vasculopathy   
Cardiac allograft vasculopathy (CAV) is a major limiting factor for long-
term survival following heart transplantation. CAV is a rapidly progressive 
form of atherosclerosis unique to transplant recipients. It is prevalent and, 
within one year, about 10% and, by 10 years, more than 50% of recipients 
are diagnosed with CAV [112]. 
 
The classical description of CAV is a diffuse concentric narrowing with 
luminal stenosis [113]. The pathogenesis is initial endothelial injury, 
followed by intimae hyperplasia and the proliferation of vascular smooth 
cells that lead to a diffuse luminal stenosis of the coronary arteries [46]. 
There are histological difference between CAV and coronary arteriosclerosis. 
Coronary arteriosclerosis is non-circumferential, focal and often presents 
proximally within the epicardial arteries. CAV is concentric, longitudinal and 
involves both intima and media (Figure 6). The whole length of the artery is 
commonly affected. Both epicardial and intramural coronary arteries are 
involved. CAV occurs in the arteries of the donor but not in the recipient 
[114]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Atherosclerosis and allograft vasculopathy. Reproduced with permission 
from N Engl J Med. 2003;349:829.Copyright MassachusettsMedical Society 
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CAV is a complex, multifactorial process. Both immunological and non-
immunological risk factors have been implicated in the pathogenesis of CAV 
[112, 115-117]. Immunological factors associated with CAV are the 
development of donor-specific human leukocyte antigen (HLA) antibodies 
[118, 119] and acute rejection [120, 121]. Non-immunological risk factors 
include donor or recipient history of hypertension, increasing donor age, 
hyperlipidemia and hyperglycaemia, among others [112]. 
 
CMV may play an essential role in CAV progression [122, 123]. Following 
primary infection, CMV remains latent in CD34+ bone marrow progenitor 
cells and monocytes and frequently reactivates [16]. The endothelial cell 
appears to be a target for CMV. Evidence of a link between CMV and CAV 
has been presented [39, 124, 125], whereas other studies have not confirmed 
these findings [126, 127]. 
 
Coronary angiography is the method for diagnosing CAV and 
arteriosclerosis. In the mid-1990s, intravascular ultrasound (IVUS) was used 
to detect silent CAV [128]. Although IVUS is more sensitive for diagnosing 
early CAV, coronary angiography is still the most commonly used method. 
The classification of angiographic CAV has to include a description of the 
maximum stenosis of the following vessels in the heart; left main artery, 
primary vessels and secondary branch vessels. The recently recommended 
classification of CAV from ISHLT is from 2010 and is reported by Mehra et 
al. [129]. 
 
Most patients are unable to experience typical angina associated with 
myocardial infarction or ischemia because of denervation of the donor heart 
and, as a result, CAV typically presents as a silent myocardial infarction, 
severe arrhythmia or sudden death. Once CAV is established, the therapeutic 
options are limited and are only palliative to slow the progression of the 
disease [130]. 
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1.6 Immunosuppression 
Induction 
Antithymocyte globulin (ATG) is a preparation created from rabbits or 
horses with antibodies against human T cells and it acts to deplete T cells. It 
is given together with glucocorticoids and antihistamine to prevent or reduce 
infusion-related symptoms. Lymphocyte subsets (CD3) may be followed to 
determine whether to administer the following dose. 
Other drugs used internationally are basiliximab and alemtuzumab. 
Basiliximab is a chimeric murine/human monoclonal antibody preparation 
that is specific to and binds with high affinity to the alpha subunit of the 
interleukin-2 receptor (IL-2R, CD25) on activated T cells. This agent thus 
inhibits the IL-2-mediated proliferation and differentiation of T cells but does 
not deplete them. Alemtuzumab is an antibody directed toward the CD52 
antigen that is present on virtually all lymphocytes, both T and B cells. 
Alemtuzumab leads to the depletion of T cells through complement-mediated 
and direct cellular cytotxicity. 
Maintenance immunosuppression 
Most maintenance immunosuppressive regimens are three-drug regimens 
consisting of a glucocorticoid, a calcineurin inhibitor (cyclosporine, 
tacrolimus) and an antimetabolite agent (mycophenolate or azathioprine). 
Glucocorticoid 
Glucocorticoid inhibits both cell-mediated and humoral immunity. The 
majority of lung transplant recipients stay on prednisone for life, while heart 
transplant recipients stay on prednisone for at least one year.  
Azathioprine 
Azathioprine (AZA) was the first successful immunosuppressive agent. It is a 
purine analogue and it is thought to act by inhibiting DNA replication and 
thus blocking the proliferation of lymphocytes [131]. A common side-effect 
is myelosupression, especially leucopenia. The drug is rarely used today. 
Mycophenolate mofetil 
Mycophenolate mofetil (MMF) was introduced in the mid-1990s and it is an 
antimetabolite agent. MMF is converted in the liver to its active form, 
mycophenolic acid (MPA), which depletes guanosine nucleotides in T and B 
lymphocytes and the proliferation of T- and B-lymphocytes is thus inhibited 
[132]. The main toxicity is from the gastrointestinal tract and 
myelosuppression. 
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Cyclosporine 
Cyclosporine (CsA) was introduced at the beginning of 1980s and it has been 
the cornerstone of immunosuppression for many years. CsA is a lipophilic 
cyclic peptide of 11 amino acids, isolated from fungi. CsA is a calcineurin 
inhibitor. Calcineurin is a protein phosphate that is critical for T-cell 
activation. The effect is exerted through binding to cyclophilins; it inhibits 
the transcription of interleukin 2 in T cells and thus prevents the proliferation 
of T cells. Nephrotoxicity is the most common and also the most important 
clinically adverse effect [131, 133]. Other side-effects are dyslipidemia, 
hypertension, gingival hyperplasia and hirsutism. 
Tacrolimus 
Tacrolimus (TAC) was introduced in the mid-1990s and it is currently the 
most widely used calcineurin inhibitor. It is a macrolide antibiotic isolated 
from fungi. TAC binds to the cytoplasmic immunophilin and inactivates 
calcineurin. This leads to the inhibition of interleukin 2 and the inhibition of 
T-cell activation and proliferation. Nephrotoxicity is a common side-effect. 
TAC is associated with less dylipedemia and hypertension compared with 
CsA, but new-onset diabetes mellitus is observed more frequently in TAC 
compared with CsA.Nephrotoxicity in CsA and TAC manifests as an acute 
increase in serum creatinine. It is mostly reversible after dose reduction, but 
it may be chronic and progressive. Both drugs have narrow therapeutic 
windows and careful monitoring of blood levels is necessary. 
Mammalian target of rapamycin (mTor) inhibitor 
The mammalian target of rapamycin (mTor) inhibitors, everolimus and 
sirolimus, exert their effect by binding to FKBP12, a member of the 
immunophilin protein family. The mTOR inhibitor FKBP12 complex blocks 
the mTOR, thereby interrupting DNA and the protein synthesis and 
proliferation of T, NK, and B cells. Both everolimus and sirolimus inhibit 
fibroblast proliferation and this may result in poor wound healing.  
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Figure 7. Immunosuppressive drugs and sites of action.                                         
MPA denotes mycophenolic acid (MMF). CTLA 4-Ig denotes betalacept. Anti-CD 25 
mAb denotes simulect. Anti CD52 mAb denotes alemtuzumab. The following drugs 
are not used for solid organ transplants today: anti-CD3 mAb, JAK3 inhibitor, 
FK778 and FTY 720. Reproduced with permission from N Engl J Med. 2004; 351: 
2715. Copyright Massachusetts Medical Society 
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2 AIMS 
 
The overall aims of this thesis were to study different aspects of CMV 
infection in lung and heart transplant patients. The specific aims were to: 
 
 
 Investigate the impact of CMV infection and disease on 
survival and BOS-free long term survival in lung transplant 
recipients 
 
 Relate the incidence and severity of CMV infection and 
disease in lung transplant patients in relation to different 
drugs and durations of antiviral prevention 
 
 Compare oral ganciclovir with valganciclovir with respect 
to incidence, severity of CMV infection or disease and acute 
rejection in lung transplant recipients 
 
 Investigate the impact of CMV, both asymptomatic 
infection and disease, on survival and CAV-free long-term 
survival in heart transplant recipients  
 
 Compare pre-emptive treatment and low-dose 
valganciclovir prophylaxis in heart transplant patients. 
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3 PATIENTS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
All the patients in the studies were transplanted at Sahlgrenska University 
Hospital in Gothenburg. Re-transplants and patients who died within 30 days 
after transplantation were excluded from the studies. 
 
3.1 Lung transplant patients and study 
design 
Paper I 
A retrospective study of 187 lung and heart-lung transplant patients 
transplanted between January 1990 and December 2002. The majority were 
women, 61% (n=114). Their mean age was 45 years (range 7-68 y). The type 
of transplantations was single lung in 58% (n=109), bilateral lung in 26% 
(n=49) and heart-lung in 16% (n=29). 
 
Lung 
transplantation 
Paper I 
187 patients 
1990-2002 
Paper II 
114 patients 
2001-2006 
Heart 
transplantation 
Paper III 
226 patients 
1988-2000 
Paper IV 
73 patients 
2008-2012 
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The pre-operative diagnoses were chronic obstructive pulmonary disease 
(COPD) in 29%, α-1-antitrypsin deficiency with emphysema in 23%, 
Eisenmenger’s syndrome in 12%, idiopathic pulmonary arterial hypertension 
in 9%, idiopathic pulmonary fibrosis in 9%, cystic fibrosis in 8% and others 
in 10% of patients 
The incidence and severity of CMV infection or disease with different CMV 
prevention and the impact of CMV as such on the development of BOS were 
studied. Medical records were reviewed. Signs and symptoms of CMV 
infection were registered. Tissue-invasive disease, such as CMV pneumonitis 
and gastrointestinal CMV, was detected with typical morphological changes 
and IHC with monoclonal antibodies to CMV. Retinitis was confirmed by an 
ophthalmologist. Pulmonary function was followed with spirometry.  
 
Paper II 
A retrospective study of 114 lung and heart-lung transplant patients 
transplanted between January 2001 and December 2006. The majority of the 
patients were women, 63% (n=72), and their mean age was 49 years (range 
10-68y). The type of transplantation was single lung in 70% (n=80), bilateral 
lung in 27% (n=31) and heart-lung in 3% (n=3). 
The pre-transplant diagnoses were chronic obstructive pulmonary disease in 
38%, idiopathic pulmonary fibrosis in 20%, alpha-1 antitrypsin deficiency 
with emphysema in 18%, cystic fibrosis in 6%, pulmonary arterial 
hypertension and pulmonary hypertension in 6%, graft-versus-host disease in 
3.5%, scleroderma in 3.5%, Eisenmenger’s syndrome in 2% and others in 3% 
of patients  
The impact of CMV on the development of BOS was studied. Pulmonary 
function was registrered (spirometry with FEV1). The patients were followed 
for four years or until death. In a subcohort of 88 CMV seropositive patients, 
oral ganciclovir (3 months) and valganciclovir (3 months) were compared. 
The incidence and severity of CMV infection/disease and acute rejection 
within the first 12 months after transplantation were registered and compared 
for the drugs. 
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3.2 Heart transplant patients and study 
design 
Paper III 
A retrospective study of 226 heart transplant patients transplanted between 
January 1988 and December 2000. The majority were male, 78% (n=176). 
Their mean age was 45 years (range 14-65y). 
The pre-transplant diagnoses were dilated cardiomyopathy in 53% (n=119), 
ischemic heart disease in 32% (n=73), myocarditis in 4% (n=9), congenital 
heart disease in 4% (n=8), valvular heart disease in 3% (n=7), 
arrhythmogenic right ventricular dysplasia in 2% (n=5), hypertrophic 
cardiomyopathy in 2% (n=5) and restrictive cardiomyopathy in 0.4% (n=1) 
of patients 
The incidence of CMV infection and disease during the first year and acute 
rejection, defined as the total or any rejection score at three, six, nine and 12 
months after transplantation, was studied. Data were collected from medical 
records. The results of coronay angiography were re-evaluated by a 
cardiologist. CMV infection and disease was diagnosed with laboratory 
methods described in the next section. Survival and CAV-free survival 
within 10 years after transplantation were analysed.  
Paper IV 
A retrospective study of 73 adult CMV seropositive heart transplant patients 
transplanted between January 2008 and December 2012.  
The pre-transplant diagnoses were dilated cardiomyopathy in 58% (n=42), 
hypertrophic cardiomyopathy in 4% (n=3), restrictive cardiomyopathy in 3% 
(n=2), ischemic heart disease in 16% (n= 12), congenital heart disease in 8% 
(n= 6) and others in 11% (n=8) of patients 
They were divided into two cohorts, an historical cohort with pre-emptive 
therapy (n=31) and a cohort with three months of low-dose VGCV 
prophylaxis (n=42). In the pre-emptive cohort, 71% were male and the mean 
age was 50 (±15 y) and, in the valganciclovir cohort, 74% were male, with a 
mean age of 51 (±14 y). No significant difference in pre-transplant diagnosis 
was found in the two cohorts. 
The incidence and severity of CMV infection and disease was compared in 
the two cohorts. Myelosuppression, especially leucopenia and kidney 
function, was evaluated. 
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3.3 Definitions in lung transplant patients 
CMV pneumonitis 
To identify CMV pneumonitis, clinical signs and symptoms such as fever, 
cough, dyspnea and hypoxia were recorded. CMV pneumonitis was verified 
from a biopsy with typical morphological changes, with viral inclusion 
bodies or IHC using monoclonal antibodies to identify early and late CMV 
antigens, together with parenchymal diffuse or perivascular inflammation. 
The grading of the severity of pneumonitis was mild, moderate and severe, 
for details see the method section in Papers I and II. Broncoscopies with 
TBB and BAL were monitored regularly at 0.5, 1, 2, 3, 4.5, 6, 9 and 12 
months after transplantation. A control biopsy was taken four weeks after 
CMV pneumonitis was treated. Biopsies were analysed with histopathology 
and IHC with CMV-specific antibodies (Papers I and II). 
Non-pulmonary CMV infection and disease  
To identify non-pulmonary infection and disease, quantitative or qualitative 
CMV PCR from blood or serum were recorded, together with clinical signs 
and symptoms. A biopsy from tissue, from the gastrointestinal tract, for 
example, was diagnosed with morphological changes and/or IHC (Papers I 
and II). 
Acute rejection 
Acute cellular rejection was diagnosed by the presence of perivascular and/or 
interstitial mononuclear infiltrates.A bronchoscopy with TBB was assessed at 
0.5, 1, 2, 3, 4.5, 6, 9 and 12 months. TBB was repeated four weeks after 
episodes of acute rejection and also when rejection was suspected. The 
grading of the severity of acute rejction is based on the degree of 
inflammation, according to the ISHLT pathological scoring system (A1 = 
minimal AR, A2 = mild AR, A3 = moderate AR, A4 = severe AR) [89]. The 
method used to compare acute rejection was the CAR score divided by the 
number of evaluable TBBs. The method based on CAR score and CAR score 
divided by the number of evaluable TBBs has been used elsewhere and 
reported in other studies [37, 41, 134, 135]. We also compared at least one 
episode of mild AR (i.e. AR grade ≥ 1) and one or two treatable acute 
rejections (i.e. AR grade ≥ 2) within three and 12 months after 
transplantation (Paper II). 
 
Bronchiolitis obliterans syndrome  
Pulmonary function tests consisted of spirometry with FEV1. A baseline 
FEV1 value was calculated and this baseline value was used to compare 
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FEV1 values, to calculate a patient’s BOS grade every year. Classification 
was made according to the classification from 1993: BOS 0: FEV1 80% or 
more of baseline, BOS 1: FEV1 66-80% of baseline, BOS 2: FEV1 51-65% 
of baseline, BOS 3: FEV1 < 50% of the baseline value [45] (Papers I and II).  
3.4 CMV prevention and treatment in lung 
transplant patients 
Prior to November 1992, only oral aciclovir was given as CMV prophylaxis, 
after which all R+ were given four weeks of i.v. ganciclovir. In January 
2001, the prophylaxis for R+ was switched to oral ganciclovir for 14 weeks 
and, since December 2003, valganciclovir for three months has been used. 
In 1997, the first D+/R- lung transplantation was carried out. Antiviral 
prevention was given for a minimum of six weeks with i.v. ganciclovir, 
followed by oral ganciclovir for at least eight additional weeks. From May 
2002, oral ganciclovir was given for 14 weeks and, in December 2003, the 
prophylaxis was changed to valganciclovir for six months. Between 1997 and 
2006, CMV IG was added on day 0, 7, 14, 35, 56 and 77 after transplantation 
(Papers I and II). 
CMV pneumonitis was treated with 5 mg/kg of i.v. ganciclovir twice daily 
for at least 14-21 days. A control biopsy was performed four weeks after the 
start of treatment and, if CMV was found, the patients received additional 
treatment. Patients with hypoxia also received 0.5 g/kg of IVIG every other 
day until an improvement was seen (maximum five doses). Foscavir was an 
alternative when patients did not respond to ganciclovir or ganciclovir 
resistance was found. In recent years, 900 mg x 2 of VGCV has been an 
alternative for treating a mild infection (Papers 1 and II). 
 
3.5 Immunosuppression in lung transplant 
patients 
Induction therapy: since 1993/1994, ATG has been the standard induction 
therapy, initially 2.5 mg/kg/day for three to 10 days. From 1998, the ATG 
doses were based on daily CD3-positive T lymphocyte cell counts. An initial 
ATG dose of 2.0 mg/kg body weight/day was given, followed by 1.5 mg/kg 
once daily when the CD3-positive T lymphocyte count exceeded 0.05 x 10
9
/l. 
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In most cases, two to four doses of ATG were given. Methylprednisolone 
was given together with ATG (Papers I and II). 
Maintenance therapy: triple immunosuppression therapy with a calcineurin 
inhibitor (CsA or TAC), an antimetabolite (AZA or MMF) and a 
corticosteroid was standard. AZA was regulary replaced with MMF from 
December 1997. Immunosuppressive treatment in 2000-2006 is described in 
detail in Paper II. 
3.6 Definitions in heart transplant patients 
CMV infection and disease 
The methods for detecting CMV replication were serology (seroconversion 
post-transplantation), viral culture, qualitative PCR for CMV DNA, biopsies 
with histopathology and IHC with CMV-specific antibodies (Table 1). 
Clinical signs and symptoms were recorded. The diagnoses were CMV 
disease, asymptomatic CMV infection and no CMV infection in accordance 
with Ljungman et al. [31]. Between 1988 and 1997, serological analyses 
were repeated once monthly for the first four months post-heart 
transplantation, then after six, nine and 12 months and thereafter annually 
and when infection was suspected. Qualitative PCR has been evaluable since 
1992 (Paper III). 
  
 
Table 1. Laboratory tests to detect CMV infection in heart transplant 
patients in different time periods  
 
Period 
 
CMV    
serology 
 
Viral 
culture 
 
Biopsy 
tissue 
 
Qualitative   
CMV PCR 
 
Quantitative 
CMV PCR 
1988-1991 + + + - - 
1992-1997 + (-) + + - 
1998-2000 (-) (-) + + - 
2001-2014 (-) (-) + - + 
The table shows the laboratory test used in our studies of heart transplantations 
 
Between 2008 and 2012, QNAT from serum was monitored weekly during 
the hospital stay and thereafter at three, four, five, six and 12 months. The 
method is described in detail by C. Kullberg-Lindh et al. [136] (Paper IV). 
Inger Johansson 
37 
Acute rejection  
All endomycardial biopsies were reclassified according to the ISHLT 
Classification from 2004 [91]. ISHLT Standardised Cardiac Biopsy Grading 
from 2004 is adopted from Stewart et al. [91]. 
 Grade 1R, mild AR: interstitial and/or perivascular infiltrate with 
up to one focus of myocyte damage. 
 Grade 2R, moderate AR: two or more foci of infiltrate with 
associated myocyte damage 
 Grade 3R, severe AR: diffuse infiltrate with multifocal myocyte 
damage ± oedema ± haemorrhage ± vasculitis 
 
At our centre, endomyocardial biopsies to detect AR (and also CMV 
myocarditis) were performed weekly according to the protocol during the 
first six weeks, thereafter at two-week intervals until three months, monthly 
from three to six months and then every three months or on clinical 
indication until 12 months after transplantation. A control biopsy was taken 
seven to 10 days after a treated rejection (Paper III). For a description of the 
total rejection score and any rejection score, see the method section in Paper 
III. 
Coronary artery vasculopathy 
Angiographic CAV is defined as mild (≤ 50% stenosis), moderate (50%-70% 
stenosis) and severe (> 70% stenosis) stenosis of the left main coronary 
artery [137]. The patients were followed with angiography annually for 10 
years (with a few exceptions) or until death. 
 
3.7 CMV prevention and treatment in heart 
transplant patients  
Different approaches to CMV prophylaxis were used during the study years; 
no CMV prophylaxis, targeted prophylaxis, pre-emptive therapy and 
universal prophylaxis.  
For treatment 5 mg/kg of i.v. ganciclovir twice daily was given for two to 
three weeks. In recent years, 900 mg of valganciclovir twice daily has been 
used for mild disease. Foscarnet was an alternative.  
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3.8 Immunosuppression in heart transplant 
patients 
Induction therapy: in 1988-1993, CsA was given as induction therapy, apart 
from the first nine patients transplanted in 1988 who received 100 mg/day of 
prednisone for three weeks. From 1993/1994, 2.5 mg/kg/day of ATG for 
three to five days was the standard. In 2008, the doses were based on daily 
CD3-positive T lymphocyte cell counts. An initial ATG dose of 2.0 mg/kg 
body weight/day was given, followed by 1.5 mg/kg once daily when the 
CD3-positive T lymphocyte count exceeded 0.05 x 10
9
/l. Since 2010, 
standard induction has been reduced to 1 mg/kg/day of ATG for three days. 
Methylprednisolone is administered together with ATG. 
Maintenance therapy: since 1994, at the very least, standard 
immunosuppression treatment was a calcineurin inhibitor (CsA or TAC), an 
antimetabolite (AZA or MMF) and a corticosteroid. In the late 1990s, AZA 
was replaced by MMF. CsA was switched to TAC if patients had repeated 
rejections. Immunosuppresive therapy for 2001-2006 is described in detail in 
Paper II. 
 
Statistical analyses 
Descriptive statistics were calculated for continuous variables, frequencies 
and proportions for categorical variables. The chi-square test was used to 
compare proportions and occurrences between the groups. The Mann-
Whitney test, as we were dealing with ordinal data (Paper II), and 
comparisons with respect to continuous variables, as most of them had a 
skewed distribution deviating from normal distribution, were used (Paper 
IV). Confidence intervals were calculated using a normality approximation 
algorithm. Survival analysis was performed using the Kaplan–Meier 
procedure and statistical comparisons of survival distributions between 
different categories were made using the log rank test (Papers I, II and III). 
Cox’s regression was used to confirm results in a multiple model after 
including possible confounding variables (Paper III). Statistical significance 
was set at the 5% level, i.e. p < 0.05. The data were analysed using SPSS 15-
22 (SPSS Inc., Chicago, IL, USA). 
 
Ethics 
This research was approved by the local ethics committee at Sahlgrenska 
University Hospital, Gothenburg, Sweden. 
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4 RESULTS 
4.1 Lung transplant patients 
Incidence of CMV disease 
Of the 187 lung transplant (LTx) patients transplanted between 1990 and 
2002, CMV pneumonitis verified by TBB (with or without symptoms) was 
found in 58% (n=109) of the patients. Six per cent (n=11) of the patients 
were diagnosed with gastrointestinal (GI) CMV. One per cent (n=2) suffered 
from retinitis. Between 2001 and 2006, CMV disease was found in 29% 
(n=33) of the 114 LTx patients. Eight per cent (n=9) had GI CMV. No 
retinitis was found (Papers I and II). 
Severe CMV pneumonitis  
Severe CMV pneumonitis was seen in 10% (n=19) of the patients in 1990 to 
2002. Three patients died of CMV pneumonitis. One additional patient died 
of CMV pneumonitis, together with a co-infection with the fungi Aspergillus 
fumigatus (Paper I). In the next study of 114 LTx patients transplanted from 
2001-2006, 4% (n=5) were diagnosed with severe CMV pneumonitis and one 
of them died (Papers II). 
Impact of CMV serostatus 
The impact of CMV serostatus was significant. CMV disease was found as 
follows: for D+/R- 88%, for D+/R + 40%, for D-/R + 28% and for D-/R- 0%. 
In the more recent period, 2001-2006, the impact of CMV serostatus from 
donor and recipient was still high. The incidence of CMV infection/disease 
was 65% for D+/R-, 39% for D+/R+, 27% for D-/R + and 11% for D-/R- 
(Papers I and II). 
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Outcome of different prophylaxis to R+ 
During the study period, four different prophylaxis regimens were given to 
CMV seropositive patients. With aciclovir for at least four weeks, 38% of 
patients were diagnosed with CMV disease, with four weeks of i.v. 
ganciclovir, 39% on average, with oral ganciclovir for threee months, 32%, 
and, with valganciclovir for three months, 20% of patients were diagnosed 
with CMV disease (Table 2). The incidence of CMV infection/disease was 
lower in the valganciclovir cohort compared with the oral ganciclovir cohort 
(24% vs. 54%, p=0.003). There was a trend towards a lower incidence of 
CMV disease in the valganciclovir cohort (20% vs. 33%, p=0.17) (Papers I 
and II). 
 
Table 2. Episodes of CMV disease and asymptomatic CMV infection during 
the first 12 months in 209 R+ lung transplant recipients (Papers I and II) 
 
Prophylaxis  
Disease % 
  Total  
          
       Severe 
Disease % 
Moderate  
  
Mild 
Infection % 
            
 No CMV % 
 
Oral ACV  38 19 5 14 33 29 
i.v. GCV  39 13 19 7 22 39 
Oral GCV   32 0 22 11 22 46 
VGCV  20 4 10 6 4 76   
Aciclovir (ACV) was given to 21 patients. From November 1992 to December 2000, four 
weeks of i.v. ganciclovir (GCV) was given to 100 patients. In January 2001, the CMV 
prophylaxis was changed to oral GCV for three months and, since 2004, valganciclovir 
(VGCV) has been given for three months. Oral GCV was given to 37 patients and VGCV to 
51 patients.  
 
The onset of CMV disease in the aciclovir cohort was a mean of 41 days 
(range: 23-65) post-transplantation and, with four weeks of i.v. ganciclovir, a 
mean of 75 days (range: 40-177). The onset of CMV infection/disease with 
oral ganciclovir for three months was 163 days (range: 100-270) and, with 
valganciclovir for three months, 136 days (range: 23-201) (Papers I and II). 
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Outcome of different prophylaxis to D+/R- 
Seventeen D+/R- patients were transplanted in 2001 to 2006. Between 2001 
and 2003, oral ganciclovir for three months was given to eight patients and, 
in 2004 to 2006, nine patients received valgancilovir for six months. In 
addition, all patients received six doses of CMV IG. The demographics were 
homogeneous for type of transplantation, age and gender. Six of the eight 
(75%) patients with oral ganciclovir prophylaxis developed CMV 
pneumonitis as compared with four of nine (45%) with valganciclovir 
prophylaxis. With oral ganciclovir, four of eight had GI CMV disease, while 
there were none in the valganciclovir cohort. One patient was diagnosed with 
ganciclovir resistance in the valganciclovir cohort, while there were none in 
the ganciclovir cohort (unpublished data).  
Acute rejection with different prophylaxis to R+ 
Three months of oral ganciclovir prophylaxsis was compared with three 
months of valganciclovir prophylaxis in 88 R+ patients. Acute rejection was 
less frequent in the valganciclovir group during the entire first year. The 
cumulative acute rejection score (CAR score) divided by the number of 
evaluable TBBs decreased significantly in the valganciclovir group. At least 
one episode of acute rejection grade 1 or acute rejction ≥ 2 was significantly 
decreased in the valganciclovir group. Minimal or no changes were made in 
the immunosuppressive regimens in 2001-2003, when oral ganciclvir was 
used as prophylaxis, and from 2004 to 2006, when valganciclovir was used 
as prophylaxis. The incidence of AR is shown in Table 4 in Paper II. 
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Survival at 10-year follow–up in lung transplant patients 
The overall one-, five- and 10-year survival rates in the 30-day survivors of 
LTx patients, in our study group of 187 patients, were 89%, 66% and 47% 
respectively. CMV disease had a significant negative impact on survival, 
with a 10-year survival of only 32% as compared with 53% after 
asymptomatic CMV infection and 57% with no CMV (p < 0.001) (Figure 8) 
(Paper I)  
Between 2001 and 2006, the six-year survival was lower among patients with 
CMV disease (64%, p = 0.042) and asymptomatic CMV infection (55%, p = 
0.018) as compared with patients with no CMV infection (84%) (Paper II). 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Survival related to CMV infection among 187 patients followed for 10 
years. The difference in survival among patients with CMV disease (n = 70), 
asymptomatic CMV infection (n = 39) and no CMV infection (n = 78) was 
statistically significant; p = 0.001 by log rank test, Kaplan-Meyer survival curve.  
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BOS-free survival at four-year follow up 
BOS-free survival was reduced in patients with CMV disease compared with 
patients with no CMVinfection (Papers I, II) 
Between 1990 and 2002, CMV disease was associated with a statistically 
significant increase in BOS-free survival (p=0.037) in 168 LTx patients at 
both one and two years after transplantation (Figure 2 in Paper I). BOS-free 
four-year survival in 107 LTx patients, between 2001 and 2006, is illustrated 
in Figure 9. FEV1 was followed for the entire four years (or until death) for 
all patients. BOS-free four-year survival for patients with CMV disease was 
32%, (p = 0.005), for asymptomatic CMV infection 36%, (p = 0.061) as 
compared with patients without CMV infection (69%). BOS-free survival 
was 2.9 (95% CI 2.6-3.2) years on average for the total group (Paper II). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. BOS-free survival in 107 lung transplant recipients related to CMV 
disease. No CMV infection (n = 65), asymptomatic CMV infection (n = 11), CMV 
disease (n = 31). BOS-free four-year survival for patients with CMV disease was 
significantly reduced as compared with no CMV (p = 0.005). Kaplan-Meyer survival 
curve. 
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4.2 Heart transplant patients 
Incidence of CMV disease 
CMV disease was found in 28% of patients and, of them, 12% (n=26) were 
diagnosed with tissue-invasive disease and 17% (n=38) with CMV syndrome 
(Paper III). 
CMV disease 
Tissue-invasive disease was found in 26 of 226 (12%) of the patients. 
Myocarditis was diagnosed in 12 patients by histopathology and/or IHC with 
CMV-specific antibodies. It was possible to establish the diagnosis as 
endomyocardial biopsies (EMB) were performed frequently during the first 
three months after transplantation (i.e. weekly according to the protocol 
during the first six weeks, thereafter every two weeks until three months). 
Two of the patients with myocarditis had additional symptoms; one patient 
had symptoms from the upper gastrointestinal tract (verified by IHC from the 
stomach) and one patient had symptoms of pneumonia (with positive 
qualitative CMV PCR from BAL fluid). 
Pneumonitis was found in five patients. Two of them had CMV verified from 
TBB or BAL by typical morphological characteristics or IHC for CMV. The 
third patient had a positive viral culture from BAL fluid. There were also two 
patients with probable CMV pneumonitis. These patients had symptoms 
from the respiratory tract and qualitative CMV PCR from BAL fluid was 
found. One of them also had a positive culture from blood.  
Gastro-intestinal disease was found in seven patients. The diagnosis was 
verified in four patients in biopsies and IHC from the gastro-intestinal tract. 
An additional three patients had severe symptoms from the gastrointestinal 
tract and positive qualitative PCR in serum.  
Nephritis (n=1) was diagnosed in a biopsy from the kidney and verified with 
IHC.  
Retinitis (n=1) was found in one patient, diagnosed by an ophthalmologist. 
Hepatitis was not diagnosed as a liver biopsy was lacking. Some of the 
patients with CMV syndrome (with fever and leucopenia) had elevated liver 
enzymes. 
CMV syndrome was diagnosed in 17% of the patients (38/226). 
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Impact of CMV serostatus 
In the total group of 226 patients, the incidence of CMV disease was 65% in 
D+/R-, 21% in D+/R+, 17% in D-/R+ and 13% in D-/R-. It is worth noting 
that only 5% (11 of 226) of patients received universal CMV prophylaxis in 
1988-2000. 
Outcome of different CMV prophylaxis to D+/R-  
We found that, without prophylaxis and pre-emptive treatment, an average of 
70-73% of the patients suffered from CMV disease. Asymptomatic CMV 
infection was diagnosed in 25-20% and no CMV infection in 5-6%. A dose 
of 1,000 mg of ganciclovir three times daily reduced the incidence of CMV 
disease to 45% (Table3) (Paper III). 
The onset of CMV disease in D+/R- without prophylaxis occurred a mean of 
57 (range 22-178) days after transplantation. With oral ganciclovir for 14 
weeks, CMV disease occurred a mean of 103 (range 64-156) days post-heart 
transplantation (Paper III). 
 
Table 3. Incidence of CMV infection and disease in 46 D+/R- heart 
transplant patients between 1988 and 2000 (Paper III) 
Period Prophylaxis CMV 
disease 
CMV 
infection 
No 
CMV 
1988-1991 
n=20 
No prophylaxis 14 (70%) 5 (25%) 1 (5%) 
1992-1997 
n=15 
Pre-emptive therapy
 
11 (73%) 3 (20%) 1 (6%) 
1998-2000 
n=11 
Oral ganciclovir 14 
weeks  
5 (45%) 3(27%)  3(27%) 
D+/R-: CMV seropositive/recipient negative patients. Pre-emptive therapy: when 
CMV DNA from serum was detected, patients received treatement with 5 mg/kg of 
i.v. ganciclovir for at least 10 days. CMV infection = asymptomatic CMV infection. 
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Outcome of different prophylaxis to R+  
The incidence or CMV disease was 19-20% on average with no prophylaxis 
or with targeted prophylaxis, while asymptomatic CMV infection was 
detected in 13-22% of the patients (Table 4). 
The onset of CMV disease in the R+ group (n=11) occurred without 
prophylaxis a mean of 45 (range 19-86) days and, with targeted 
prophylaxis (n=21), a mean of 51 (range 17-151) days post-
transplantation (Paper III). 
 
Table 4. Incidence of CMV infection and disease in 165 R+ heart 
transplant recipients between 1988 and 2000 (PaperIII) 
Period Prophylaxis CMV 
disease 
CMV 
infection 
No 
CMV 
1988-1991 
n=59 
No prophylaxis 11 (19%) 8 (13%) 40(68%) 
1992-2000 
n=106 
Targeted 
prophylaxis
1 
21 (20%) 23 (22%) 62(58%) 
1
Targeted prophylaxis consisted of 5 mg/kg of i.v. ganciclvoir twice daily for 10 
days in association with the first anti-rejection treatment with ATG/OKT3 and the 
second anti-rejection treatment with high-dose corticosteroids within the first four 
months post-transplantation. 
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In the more recent period between 2008 and 2012, the result was as follows. 
With pre-emptive therapy, CMV disease was found in 10% of the patients (3 
of 31); one case of non-invasive disease (CMV syndrome) and two cases of 
tissue-invasive disease presenting as gastritis and colitis. With 450 mg of 
valganciclovir daily for three months, no CMV disease was found during the 
first year after transplantation (Table 5). The peak of viral load was detected 
after a mean of 68 days (range 18-184) in the pre-emptive cohort, while the 
corresponding figure was 96 days (range 10-251) in the prophylaxis cohort. 
 
 
Table 5. Incidence of CMV infection and disease in 73 CMV seropositive 
heart transplant patients between 2008 and 2012 (Paper IV) 
Period Prophylaxis CMV 
disease 
CMV 
infection 
No 
CMV 
2008-2010 
n=31 
Pre-emptive 
therapy 
3 (10%) 24 (77%)  4 (13%) 
2010-2012 
n=42 
VGCV 3 months 0 24 (57%) 18(43%) 
VGCV: 450 mg of valganciclovir daily for three months 
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Survival at 10-year follow-up in heart transplant patients 
Survival for patients with CMV disease was 7.0 years (95% CI 6.0-7.9), with 
asymptomatic CMV infection 7.5 years (95% CI 6.4-8.5) and with no CMV 
infection 8.7 years (95% CI 8.2-9.2). The mean follow-up for survival was 
9.9 years (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Survival was significantly higher for patients with no CMV infection, 
n=116 (69%), compared with patients with CMV disease, n=64 (55%; p=0.018), 
and asymptomatic CMV infection, n= 46 (54%; p=0.053). Kaplan-Meyer survival 
curve. 
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CAV-free survival at 10-year follow up 
The CAV-free survival in heart transplant patients was 6.4 years (95% CI 
5.7-7.0) for the 116 patients with no CMV infection, 5.1 years (95% CI 4.1-
6.2) for the 46 patients with asymptomatic CMV infection and 4.1 years 
(95% CI 3.1-5.1) for the 64 patients with CMV disease. The CAV-free 
survival for the total group was a mean of 5.5 years (95% CI 4.96-5.98). 
When tested in a multiple Cox-regression model, CMV disease, 
asymptomatic CMV infection and donor age (but not recipient age, gender 
and HTx due to ischemic heart disease) were significant predictors of CAV-
free survival 10 years after transplantation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. CAV-free survival during a follow-up of 10 years in 226 heart transplant 
patients was significantly higher for patients with no CMV infection (n =116), 
compared with patients with CMV disease (n =64, p =<0.0001) and asymptomatic 
CMV infection (n =46; p =0.013), Kaplan-Meyer survival curve. 
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5 DISCUSSION 
A transplanted lung is a high-risk organ for CMV infection and heart 
transplantation entails an intermediate risk of CMV infection. We studied the 
incidence and severity of CMV infection and disease with different 
prophylactic regimens and the impact of CMV on the development of BOS 
in lung transplant recipients and CAV in heart transplant recipients. The 
discussion is divided into two parts, beginning with CMV in lung transplant 
(LTx) recipients, followed by CMV in heart transplant (HTx) recipients.  
CMV in lung transplant recipients 
What are the optimal drug, dose and duration of CMV prophylaxis to LTx 
recipients? Universal prophylaxis, not pre-emptive therapy, has always been 
the prophylactic approach at our centre. Oral aciclovir was the first drug to be 
used; late in 1992, prophylaxis was changed to i.v. ganciclovir with four 
weeks’ duration. Oral ganciclovir was introduced in 2001, followed by 
valgancilovir in 2003; both drugs were given for three months.  
In our study a dose of 1,000 mg of oral ganciclovir three times daily was 
compared with 900 mg of valganciclovir once daily in R+ patients. All 
patients received prophylaxis for three months. CMV infection and disease 
were registered for the first 12 months. We found a significantly lower 
incidence of CMV infection/disease in the valganciclovir cohort compared 
with the ganciclovir cohort. The drugs were compared in a prospective study 
by Paya et al. on effect of CMV prophylaxis in D+/R- solid organ transplant 
recipients. The authors found a higher viral suppression and a delay to 
viremia in the patients with valganciclovir prophylaxis as compared with oral 
ganciclovir. They concluded that valganiclovir was as clinically effective as 
oral ganciclovir. However, LTx patients were not included in that study 
[138]. To our knowledge, there is no prospective clinical study comparing 
the drugs in LTx patients. One possible explanation of the different effects 
found in our study is that oral ganciclovir results in a lower blood 
concentration of the drug. Valganciclovir is a prodrug of ganciclovir, with 
60% bio-availability compared with six per cent for oral ganciclovir. 
Pescovitz et al. concluded that 1,000 mg of oral ganciclovir three times daily 
is comparable to 450 mg of valganciclovir once daily [139].  
Our studies on CMV R+ recipients support a longer duration of CMV 
prophylaxis. An intravenous dose of 5 mg/kg of ganciclovir twice daily for 
two weeks, followed by 5 mg/kg once daily for an additional two weeks, was 
compared with oral ganciclovir for 14 weeks. Oral ganciclovir, which was 
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given in a dose resulting in a lower blood concentration but given for a 
longer duration as compared with i.v ganciclovir, was more effective in 
preventing of late onset CMV infection and disease. In addition, we found 
that 14 weeks of oral ganciclovir resulted in a delay in the onset of CMV 
infection/disease and also a trend towards less severe CMV pneumonitis. 
Valganciclovir given in a dose of 900 mg daily for three months to R+ LTx 
patients reduced the incidens of CMV infection and disease, but the burden 
of CMV disease was still high, 20%. A high incidence of late-onset CMV 
disease in LTx recipients (D+/R-and R+) with three months of valganciclovir 
has also been found by others [140]. CMV disease has to be reduced further 
and our findings support the hypothesis that a longer duration of prophylaxis 
to R+ LTx patients is beneficial. Zuk et al. reported in 2010 that the duration 
of prophylaxis varies at different centres from three months to indefinitely, 
with three to 12 months as the most common duration [141]. Benefits of a 
longer duration of CMV prophylaxis with valganciclovir to LTx recipients 
have been reported in different time periods [42, 103, 134, 142, 143]. A 
randomised, controlled trial compared three months of valganciclovir with 12 
months of valganciclovir to all at-risk LTx recipients (D+/R- and R+) and 
demonstrated the efficacy of a longer duration of CMV prophylaxis. One 
comment is that they only followed the incidence of late-onset CMV for six 
months after the cessation of 12 months of prophylaxis [84]. A longer 
follow-up is needed and, as a result, 38 patients from the previously 
mentioned study were followed longer, an average of four years, in a single-
centre study. They reported a sustainable effect of prophylaxis with a reduced 
risk of pneumonitis for patients who received 12 months of valganciclovir 
[144]. Two studies from 2013 highlighted the impact of donor/recipient 
CMV serostatus and recommended six months of valganciclovir to R+ and 
12 months to D+/R- LTx patients [85, 145]. The international guidelines for 
solid organ transplant recipients (Transplantation Society International CMV 
Consensus Group [32, 70] and the Americ an Society of Transplantation) 
recommend six to 12 months of CMV prophylaxis to R+ and 12 months to 
D+/R- LTx patients [77].  
Comparing studies from different centres may be difficult due to various 
definitions of CMV infection and disease, various diagnostic methods, 
various frequencies of monitoring and follow-up times. The strengths of our 
studies when we compared different types of prophylaxis are that we 
included the same definition of CMV disease and infection, the same CMV 
serostatus (R+), the same frequency of monitoring and the same diagnostic 
methods used with TBB/BAL during the whole study time, from 1990 to 
2006. 
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The optimal way to compare CMV prophylaxis in retrospective studies is to 
compare patients who are treated with the same immunosuppression. This is 
done in Paper II. In Paper I, there was a change of immunosuppressive 
therapy in 1997, when the triple immunosuppression of AZA, CsA and 
steroids was changed to MMF, CsA and steroids. Induction with ATG has 
been used throughout the whole study period, but the dose was reduced in 
1998.  
CMV disease was not detected during the prophylaxis period if an adequate 
dose of ganciclovir or valganciclovir was given. Late-onset CMV disease 
(i.e. disease after the prophylactic period ends) occurred on average 1.5-2.5 
months after the cessation of ganciclovir/valganciclovir with three months’ 
prophylaxis. It is essential to monitor frequently during this time period to 
detect CMV infection/disease when three months of prophylaxis is given. 
Future studies may identify the optimal length of the monitoring period and 
the intensity of monitoring.  
Bronchiolitis obliterans syndrome 
We found that CMV disease had a significant negative impact on 
survival. After 10 years 32% of the patients were alive and 57% of those 
without CMV infection. This impact of CMV disease on survival could 
be attributable to the infection as such, but our results also suggest that 
CMV disease increases the risk of the development of BOS. The results 
from both our studies support the idea that CMV disease is a risk factor 
for the development of BOS. We found a tendency towards lower BOS 
and histologically verified BO with valganciclovir as compared with oral 
ganciclovir. However, no significant difference between the two drugs in 
terms of 4-year survival and BOS-free 4-year survival was seen. 
 
Preventing BOS is essential, as no effective cure exists. The median survival 
after the onset of BOS is three to four years [146, 147]. BOS is manifested by 
a progressive decline in pulmonary function. The histopathological features 
of BO are that injury to and inflammation of epithelial cells and sub-
epithelial structures of small airways lead to excessive fibroproliferation, 
including ineffective epithelial regeneration. The result is a partial or 
complete obstruction into the airway lumen [148]. The pathogenesis of BOS 
is complex and the mechanisms underlying the possible association with 
CMV infection and BOS are unclear. CMV has both immunosuppressive and 
inflammatory properties [48]. Several cytokines, chemokines and growth 
factors are suggested to be involved in the pathogenesis [149]. The risk 
factors for BOS are said to be multifactorial and different medical conditions 
can lead to the same microscopic, physiological and clinical results [150]. 
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Several other studies have addressed the possible relationship between CMV 
infection and BOS [37, 40-42, 103, 104, 151, 152], but, on the other hand, 
some authors present conflicting results [105, 106, 153]. The strongest 
evidence of an association between CMV infection and BOS dates back to 
the pre-ganciclovir era.  
 
Acute rejection in lung transplant recipients 
Is there an association between CMV and acute rejection? We found that 
CMV infection/disease and acute rejection were significantly lower in the 
valganciclovir cohort, as compared with the ganciclovir cohort. Both cohorts 
had the same protocol for immunosuppression. One explanation of the lower 
rate of acute rejection among those receiving the valganciclovir prophylaxis 
could be the lower incidence of CMV infection/disease during the first year 
post-transplant. A lower CMV burden results in less inflammatory response 
in the transplanted lung(s) and fewer episodes of acute rejection may 
therefore be triggered. 
It is assumed that there is a bidirectional relationship between CMV and 
acute rejection, with several mechanisms involved in this effect. Cytokines, 
chemokines and growth factors are induced in response to both CMV 
infection and acute rejection and result in the activation of the vascular 
endothelium and inflammatory cells [26, 58]. The tumour necrosis factor 
(TNF) is released during acute rejection and is one of the most important 
proinflammatory cytokines in the reactivation of CMV from latency [58, 59]. 
As a result of same proinflammatory mediators, the histological features of 
acute rejection and CMV pneumonitis are almost the same. Distinguishing 
histologically between the two diagnoses is difficult and requires the 
detection of the CMV virus.  
 
If CMV in fact induces acute rejection, the antiviral prophylaxis should be 
able to reduce/influence the incidence of acute rejection. Our result supports 
this concept. Other authors have also found that CMV prophylaxis influences 
the incidence of acute rejection. Paraskeva et al. observed a significantly 
lower incidence of acute rejection within the first 12 months when 
valganciclovir for five months was compared with ganciclovir for three 
months, with no difference in the immunosuppression protocols between the 
two groups [37]. Jaksch et al. found that there was a positive trend towards a 
lower acute rejection score when D+/R- LTx patients received 12 months of 
valganciclovir as compared with three months [134]. 
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CMV in heart transplant recipients 
Our studies range from 1988 to 2012. The spectrum of CMV disease, the 
diagnostic tools and CMV prevention have changed during this period. In the 
1990s, myocarditis, pneumonitis, gastrointestinal disease and CMV 
syndrome were the most common forms of CMV disease. Today, the most 
common manifestation of CMV disease in HTx recipients is CMV syndrome, 
followed by gastrointestinal disease, but the myocarditis and pneumonitis are 
seldom seen. Nephritis, hepatitis and retinitis were represented at a low 
frequency during the time period. 
Viral culture and CMV-specific IgG and IgM antibodies were the available 
diagnostic laboratory methods during the late 1980s and the early 1990s. 
These laboratory methods confirmed the CMV infection/disease first when 
the patients had developed severe or moderate symptoms or had already 
recovered from a mild CMV infection. Regular, frequent endocardial 
myocardial biopsies made it possible to verify CMV myocarditis. A high 
incidence of CMV disease occurred during this period, as no prophylaxis was 
given. Qualitative PCR, an in-house nested PCR, has been available at our 
transplant centre since 1992 [154]. Quantitative PCR, Cobas Amplicor 
Monitor (Roche), has been available at our centre since 2001 [155, 156]. A 
few years later, the method was changed to quantitative real-time TacMan® 
PCR, which is the method used today [136]. 
We found that both CMV disease and asymptomatic CMV infection during 
the first year after heart transplantation had a significant influence on CAV-
free survival after 10 years of follow-up. In agreement with our results, 
other studies have shown that CMV infection may play an essential role 
in CAV progression [39, 124, 157, 158]. In some studies, however, the 
effect of CMV on CAV development has been questioned [126, 127]. The 
reason for this difference may be different definitions of CAV and the 
fact that only the influence of CMV serology, not CMV infection or 
disease, on CAV development was studied [126, 127]. CAV is a rapidly 
progressive form of arteriosclerosis unique to transplant patients. It is a 
complex multifactorial process, with both immunological and non-
immunological risk factors. The pathogenesis is endothelial injury, followed 
by intimae hyperplasia and the proliferation of vascular smooth cells that 
lead to diffuse luminal stenosis of the coronary arteries. Histologically, a 
diffuse concentric longitudinal intimal hyperplasia in the epicardial coronary 
arteries is seen. It is diagnosed with coronary angiography or intravascular 
ultrasound (IVUS). The structural changes occur in the coronary artery 
during the first year after heart transplantation and this adversely affects 
long-term survival [159-161]. CMV is capable of infecting endothelial cells 
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and smooth-muscle cells in the vascular wall, thereby causing cell damage 
[115, 122, 162]. This is just one of the characteristics of the CMV that 
explain how the virus may play a role in CAV progression. The exact role of 
CMV in CAV development, however, remains unclear [115].  
 
In 2010, our transplant centre changed CMV prophylaxis for CMV 
seropositive HTx patients from pre-emptive to universal prophylaxis. The 
reason was to reduce CMV disease and the possible negative impact of CMV 
in the long term. There have been different opinions about the best 
prophylactic approach to HTx recipients [163]. There is no randomised trial 
comparing the two different approaches to HTx. Pre-emptive therapy has the 
advantage of fewer incidences of late-onset CMV infection, theoretically 
more opportunity to develop CMV-specific immunity in addition to lower 
drug cost, reduced drug exposure and a reduced risk of developing resistant 
CMV. Universal prophylaxis is easy to implement, has a lower monitoring 
cost, may prevent other opportunistic infections, acute rejection and improve 
graft survival. CMV prophylaxis guidelines recommend a 900-mg daily dose 
of valganciclovir to prevent disease in solid organ transplant recipients [32]. 
A well-known adverse event of valganciclovir is myelosuppression, 
especially leucopenia. A low dose of valganviclovir, 450 mg daily, has been 
reported to provide effective CMV prophylaxis in liver and kidney transplant 
recipients [164, 165] Valganciclovir, 450 mg daily, is the current 
prophylactic dose for liver and kidney transplant recipients at our centre. It is 
unclear which dose of valganciclovir is needed in heart transplant patients in 
order to achieve optimal antiviral activity with minimal adverse effects. Only 
one study has been published on 450 mg of valganciclovir daily to HTx 
patients [166]. Our centre introduced low-dose valganciclovir for three 
months to CMV seropositive patients in April 2010. We compared 450 mg of 
valganciclovir daily with pre-emptive therapy in CMV seropositive HTx 
patients. None of the patients in the valganciclovir cohort was diagnosed 
with CMV disease within the first year post-transplantation. The CMV 
burden (viral load) was significantly lower as compared with the pre-emptive 
cohort. The drug was well tolerated. One concern is that the use of a 
prolonged low dose of valganciclovir may be a risk factor for the 
development of ganciclovir resistance. Some studies suggested that the 
treatment of CMV infection with sub-therapeutic doses of antiviral 
medication should be avoided [167, 168]. However, none of our patients 
developed clinical valganciclovir-resistant CMV disease. It is too early to 
evaluate the possible advantages of valganciclovir prophylaxis in the long 
term.  
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6 CONCLUSIONS 
 
 
 CMV disease reduced 10-year survival and BOS-
free 4-year survival compared with no CMV 
infection. Aggressive CMV prevention is essential 
for pulmonary function and long-term survival. 
 
 CMV prevention with 14 weeks of oral ganciclovir 
reduced the incidence and severity and prolonged 
the time to onset of CMV disease, as compared with 
4 weeks of intravenous ganciclovir, in CMV 
seropositive lung transplant patients. Our study 
supports a longer duration of CMV prevention.  
 
 A lower incidence of CMV infection/disease and 
acute cellular rejection was observed with 
valganciclovir prophylaxis when compared with 
oral ganciclovir, both administered for 3 months to 
CMV seropositive lung transplant patients. 
Valganciclovir is more effective in reducing the 
CMV burden and might even have an impact on 
acute rejection in lung transplant patients. 
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 Ten-year survival and CAV-free ten-year survival was 
significantly reduced in patients with CMV disease and 
asymptomatic CMV infection in heart transplant patients. 
Aggressive CMV prevention within the first year post-
transplant is essential to reduce CAV and increase long-term 
survival. 
 
 A low dose of valganciclovir prophylaxis (450 mg daily) to 
CMV seropositive heart transplant patients prevented CMV 
disease and significantly reduced the number of patients 
with reactivated asymptomatic CMV infection as compared 
with a pre-emptive approach. Prospective, controlled studies 
are needed to confirm these results. 
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7 FUTURE PERSPECTIVES 
During the last decade, significant advances have been made in the 
management of CMV infection. Effective drugs and viral monitoring have 
reduced the frequency of CMV disease. 
The optimal duration of CMV prevention to LTx and HTx recipients is, 
however, not known, even though a longer duration of CMV prevention to 
LTx recipients is beneficial. Low-dose valganciclovir, 450 mg, in HTx 
recipients needs to be evaluated in prospective studies, with frequent 
monitoring with QNAT to evaluate the efficacy and safety of this 
prophylaxis. Futhermore, long-term studies are needed to access the 
possible/probable causal relationship, and not only the association, between 
CMV reactivation and graft injury, such as BOS and CAV. 
There is a need for novel oral antiviral drugs for both prevention and 
treatment CMV infection and disease. Several drugs are in various stages of 
clinical development: Maribavir, an oral inhibitor of CMV UL97 kinase 
[169]. Brincidofovir, an oral bio-derivative of cidofovir, with less or no renal 
toxicity [170], Letermovir, a CMV UL56 terminase inhibitor [171] and 
Cyclopropavir, a nucleoside analogue [172]. 
 
The development of CMV vaccine is an area of research [173, 174]. The goal 
is to find a vaccine able to prevent or modulate CMV infection and/or 
disease. Clinical trials phase II and III are ongoing. TransVax DNA vaccine 
will enter a phase 3 trial [175].  
 
Immunological monitoring may be performed in the future. Assays 
commercially available today are QuantiFeron®-CMV (only detects CD8+ 
response) and ImmuKnow® (not specific for CMV). The assays may help to 
individualise CMV prophylaxis in the future, but it remains to be proved 
whether these tests are sensitive enough for LTx and HTx recipients [176-
178]. 
These are just a few of the never-ending questions that need to be answered 
when it comes to this complex and interesting virus.  
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